<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Genzyme</title><meta name="description" content="Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Genzyme Corporation, Sanofi Genzyme, Genzyme Corp"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Genzyme"/><meta property="og:title" content="Genzyme"/><meta property="og:description" content="Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent..."/><meta property="og:url" content="https://grokipedia.com/page/Genzyme"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Genzyme"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:43.101Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Genzyme"/><meta name="twitter:description" content="Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="9c03ed3de1f5d258ad48dfa1e3ed715e-f7c4bc120738ddf4-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=9c03ed3de1f5d258ad48dfa1e3ed715e,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.27816427199342897,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#genzyme" class="transition-opacity hover:opacity-100 opacity-50">Genzyme</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#founding-and-early-development-1981-1989" class="transition-opacity hover:opacity-100 opacity-50">Founding and Early Development (1981-1989)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#expansion-and-key-product-launches-1990-1999" class="transition-opacity hover:opacity-100 opacity-50">Expansion and Key Product Launches (1990-1999)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diversification-growth-and-pre-acquisition-challenges-2000-2010" class="transition-opacity hover:opacity-100 opacity-50">Diversification, Growth, and Pre-Acquisition Challenges (2000-2010)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#acquisition-by-sanofi-2011" class="transition-opacity hover:opacity-100 opacity-50">Acquisition by Sanofi (2011)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#business-operations" class="transition-opacity hover:opacity-100 opacity-50">Business Operations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#organizational-structure-and-divisions" class="transition-opacity hover:opacity-100 opacity-50">Organizational Structure and Divisions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#manufacturing-and-supply-chain" class="transition-opacity hover:opacity-100 opacity-50">Manufacturing and Supply Chain</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#global-reach-and-workforce" class="transition-opacity hover:opacity-100 opacity-50">Global Reach and Workforce</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#products-and-therapeutic-focus" class="transition-opacity hover:opacity-100 opacity-50">Products and Therapeutic Focus</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#rare-disease-therapies" class="transition-opacity hover:opacity-100 opacity-50">Rare Disease Therapies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#other-biotech-products" class="transition-opacity hover:opacity-100 opacity-50">Other Biotech Products</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research-and-development-pipeline" class="transition-opacity hover:opacity-100 opacity-50">Research and Development Pipeline</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#innovations-and-achievements" class="transition-opacity hover:opacity-100 opacity-50">Innovations and Achievements</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pioneering-orphan-drug-development" class="transition-opacity hover:opacity-100 opacity-50">Pioneering Orphan Drug Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#economic-and-medical-impact" class="transition-opacity hover:opacity-100 opacity-50">Economic and Medical Impact</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#strategic-acquisitions-and-partnerships" class="transition-opacity hover:opacity-100 opacity-50">Strategic Acquisitions and Partnerships</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-and-criticisms" class="transition-opacity hover:opacity-100 opacity-50">Controversies and Criticisms</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#manufacturing-contamination-and-product-shortages-2009-2011" class="transition-opacity hover:opacity-100 opacity-50">Manufacturing Contamination and Product Shortages (2009-2011)</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#marketing-practices-and-legal-settlements" class="transition-opacity hover:opacity-100 opacity-50">Marketing Practices and Legal Settlements</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#patient-safety-and-dosage-disputes" class="transition-opacity hover:opacity-100 opacity-50">Patient Safety and Dosage Disputes</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-engagement-and-lobbying" class="transition-opacity hover:opacity-100 opacity-50">Regulatory Engagement and Lobbying</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#interactions-with-fda-and-other-agencies" class="transition-opacity hover:opacity-100 opacity-50">Interactions with FDA and Other Agencies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#advocacy-on-intellectual-property-and-orphan-drug-policies" class="transition-opacity hover:opacity-100 opacity-50">Advocacy on Intellectual Property and Orphan Drug Policies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#post-acquisition-legacy" class="transition-opacity hover:opacity-100 opacity-50">Post-Acquisition Legacy</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#integration-into-sanofi" class="transition-opacity hover:opacity-100 opacity-50">Integration into Sanofi</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#ongoing-influence-and-recent-developments-2011-2025" class="transition-opacity hover:opacity-100 opacity-50">Ongoing Influence and Recent Developments (2011-2025)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="genzyme" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Genzyme<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Under the leadership of subsequent executives including Henri Termeer, Genzyme introduced landmark products such as Ceredase and its successor Cerezyme (imiglucerase) for Gaucher&#x27;s disease in the early 1990s, marking the first approved enzyme replacement therapy for the condition, and Fabrazyme (agalsidase beta) for Fabry disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> These innovations established a viable commercial model for orphan drugs, leveraging regulatory incentives amid high development costs and limited markets, though treatments commanded premium prices often exceeding $200,000 annually per patient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme&#x27;s growth culminated in its 2011 acquisition by Sanofi-aventis for $74 per share in cash, totaling approximately $20.1 billion, which integrated its rare disease expertise into a global pharmaceutical powerhouse while preserving the Genzyme brand for specialized operations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The company encountered significant challenges, including a 2009 viral contamination at its Allston manufacturing facility that triggered prolonged shortages of Cerezyme and Fabrazyme, resulting in patient harm allegations and ongoing litigation over rationed dosing strategies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="founding-and-early-development-1981-1989" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Founding and Early Development (1981-1989)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme Corporation was founded on June 8, 1981, in Boston, Massachusetts, by venture capitalists Sheridan Snyder and George M. Whitesides alongside scientist Henry Blair, who served as the company&#x27;s scientific founder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> The initial office and laboratory were established on the Tufts University campus in Medford, Massachusetts, with Blair leveraging his National Institutes of Health contract to focus on enzyme-based technologies for diagnostics and therapeutics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Supported by venture capital, the company quickly pursued acquisitions to build its biochemical capabilities, including Whatman Biochemicals Ltd. in 1981, which formed the basis of Genzyme Biochemicals, and Koch-Light Laboratories, a British chemical supplier, in 1982.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1983, Henri Termeer joined as chairman and president, becoming CEO in 1985, and redirected the firm&#x27;s efforts toward developing treatments for rare genetic diseases, notably enzyme replacement therapy for Gaucher&#x27;s disease using alglucerase derived from human placental tissue.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> Under Termeer, Genzyme emphasized carbohydrate and enzyme technologies, producing early diagnostic reagents such as cholesterol oxidase for cholesterol testing kits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> This period marked the company&#x27;s transition from biochemical supply to biotech innovation, with initial clinical trials for Gaucher&#x27;s therapy commencing around 1983 amid challenges in scaling enzyme production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 1986, Genzyme went public through an initial public offering that raised $28.2 million, enabling expansion including a Japanese subsidiary and a Cambridge, Massachusetts, facility for hyaluronic acid production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> The firm secured $10 million in partnerships specifically for advancing Ceredase, its Gaucher&#x27;s treatment candidate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In 1988, it opened a pharmaceutical chemical plant in Haverhill, United Kingdomâ€”partially funded by the UK Department of Trade and Industryâ€”and received FDA approval for clindamycin phosphate, an antibiotic product.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> The decade closed with the 1989 acquisition of Integrated Genetics for $31.5 million to bolster genetic engineering capabilities, additional financing of $39.1 million via stock offerings and $36.8 million for hyaluronic acid drug development, and the formation of a diagnostics division, culminating in $34.1 million in annual revenues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="expansion-and-key-product-launches-1990-1999" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Expansion and Key Product Launches (1990-1999)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
The successful launch of Ceredase (alglucerase injection) in 1991 propelled Genzyme&#x27;s expansion, marking the company&#x27;s first major commercial product for treating type 1 Gaucher disease through enzyme replacement therapy derived from human placental glucocerebrosidase. The U.S. Food and Drug Administration (FDA) approved Ceredase on April 5, 1991, following its availability outside the United States starting in 1990, which addressed a rare lysosomal storage disorder affecting approximately 20,000 patients worldwide at the time. This breakthrough drove significant revenue growth, with sales rising from $54.8 million in 1990 to $121.7 million in 1991, more than doubling the company&#x27;s financial performance and enabling further investment in biotechnology infrastructure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">To address supply constraints inherent in placental sourcing, Genzyme developed Cerezyme (imiglucerase), a recombinant human glucocerebrosidase produced via mammalian cell culture, which received FDA approval on May 23, 1994, as a more scalable alternative for Gaucher disease treatment. This product launch coincided with the opening of the Allston Landing manufacturing facility in 1996, constructed beginning in the early 1990s to support recombinant protein production, including Cerezyme, and representing a key step in Genzyme&#x27;s shift toward sustainable biomanufacturing capabilities. Revenues continued to expand, reaching $265.7 million in 1993 and $310.7 million in 1994, reflecting 17% year-over-year growth driven primarily by enzyme therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme pursued diversification through strategic acquisitions and additional product launches in the mid-to-late 1990s, including the 1992 purchases of Integrated Genetics for genetic engineering expertise, Gencore International for distribution networks, and Medix Biotech for diagnostic reagents, which broadened its therapeutic and operational scope. In 1996, the company introduced Seprafilm, a bioresorbable adhesion barrier approved by the FDA on March 25, 1996, designed to reduce postoperative adhesions in abdominal and pelvic surgeries. The following year, Carticel (autologous cultured chondrocytes) gained FDA approval in August 1997 as the first cell-based therapy for repairing knee cartilage defects, entering a nascent field of tissue engineering. These initiatives, alongside a 1996 collaboration with Imperial Cancer Research Technology Ltd. to bolster oncology research, underscored Genzyme&#x27;s evolution from a niche enzyme-focused firm to a multifaceted biotechnology leader by decade&#x27;s end.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h3 id="diversification-growth-and-pre-acquisition-challenges-2000-2010" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Diversification, Growth, and Pre-Acquisition Challenges (2000-2010)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the early 2000s, Genzyme diversified its portfolio beyond lysosomal storage disorders by acquiring companies to enter biosurgery, transplant immunology, and oncology. In 2000, it acquired Biomatrix, Inc., adding Synvisc, a viscosupplement for osteoarthritis treatment, which formed the basis of its Genzyme Biosurgery division.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> In 2001, Genzyme purchased Novazyme Pharmaceuticals for $457 million, gaining enzyme replacement therapy technology for Pompe disease, leading to the development of Myozyme (alglucosidase alfa), approved by the FDA in 2006.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Further acquisitions included SangStat Medical Corporation in 2003 for Thymoglobulin, an immunosuppressant for organ transplant rejection, and AnorMED in 2006 for plerixafor (Mozobil), a stem cell mobilizer for multiple myeloma and lymphoma patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> These moves created five focused business unitsâ€”therapeutics, biosurgery, transplant, oncology, and geneticsâ€”reducing reliance on flagship products like Cerezyme (imiglucerase) for Gaucher disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Revenue growth accelerated through product launches, international expansion, and diversified sales. From 2001 to 2006, annual sales grew at a compound annual rate of approximately 27 percent, reaching $3.19 billion in 2006, driven by increased demand for rare disease therapies and new approvals like Renagel (sevelamer) for hyperphosphatemia in chronic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> By 2010, total revenue approached $4.4â€“4.5 billion, with non-GAAP earnings per share projected at $3.85â€“$3.95, reflecting contributions from multiple segments including oncology (e.g., Campath for chronic lymphocytic leukemia, acquired via ILEX Oncology in 2004) and global manufacturing investments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup> Genzyme also unified its capital structure in 2003 by eliminating tracking stocks, streamlining operations and enabling focused R&amp;D investments exceeding $700 million annually by the late 2000s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite growth, Genzyme encountered severe pre-acquisition challenges, particularly manufacturing disruptions in 2009â€“2010 that affected supply of critical drugs. In June 2009, a viral contamination (vesivirus 211) in Chinese hamster ovary cells at the Allston, Massachusetts facility halted production of Cerezyme and Fabrazyme (agalsidase beta for Fabry disease), leading to global shortages; by July, Genzyme could meet only 50 percent of Cerezyme demand.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The FDA issued multiple warning letters, citing inadequate quality controls and particulate contamination in products, prompting a consent decree in May 2010 requiring facility upgrades and independent oversight, with potential fines up to $175 million.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> These issues caused Cerezyme sales to drop 30 percent in 2009 and overall revenue growth to stall, exacerbating investor pressure and positioning the company for acquisition amid unresolved supply constraints.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<h3 id="acquisition-by-sanofi-2011" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Acquisition by Sanofi (2011)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In February 2010, Sanofi-aventis submitted a non-binding proposal to acquire Genzyme in an all-cash transaction valued at approximately $18.5 billion, which Genzyme rejected as undervaluing the company amid ongoing manufacturing challenges and product pipeline potential.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Negotiations continued, culminating in an agreement announced on February 16, 2011, for Sanofi-aventis to acquire Genzyme for $74.00 per share in cash, representing an equity value of about $20.1 billion, plus one contingent value right (CVR) per share potentially worth up to additional payments tied to milestones such as resolution of manufacturing issues for Cerezyme and Fabrazyme and regulatory approval of Lemtrada (alemtuzumab).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> The deal addressed Genzyme&#x27;s vulnerabilities, including a U.S. FDA consent decree from 2009 over production contamination and supply shortages for critical rare disease therapies, which had eroded investor confidence and share value despite Genzyme&#x27;s leadership in enzyme replacement therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The acquisition received antitrust clearance from the European Commission on January 12, 2011, under Merger Regulation case COMP/M.5999, determining no significant competition concerns in the rare disease and biologics markets, and from the U.S. Federal Trade Commission prior to the announcement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Sanofi-aventis launched a tender offer for Genzyme shares, which expired on April 1, 2011, after sufficient acceptance to proceed, followed by a short-form merger on April 8, 2011, delisting Genzyme from NASDAQ without further shareholder vote and integrating it as a subsidiary focused on rare diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Strategically, the acquisition bolstered Sanofi&#x27;s position in high-margin rare disease treatments, diversifying from its traditional pharmaceutical portfolio into biologics and orphan drugs, where Genzyme generated over 80% of its revenue from therapies like Cerezyme for Gaucher disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Sanofi committed to investing in resolving Genzyme&#x27;s manufacturing constraints, including upgrades at facilities in Allston, Massachusetts, to restore full production capacity and mitigate supply risks that had previously led to patient rationing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> Post-acquisition, Genzyme operated semi-autonomously under Sanofi Genzyme, preserving its specialized R&amp;D focus while leveraging Sanofi&#x27;s global infrastructure for commercialization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup></span>
<h2 id="business-operations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Business Operations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="organizational-structure-and-divisions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Organizational Structure and Divisions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme Corporation maintained a divisional organizational structure designed to support specialized biotechnology development and commercialization in niche therapeutic areas, with each division operating semi-autonomously to address distinct market needs and regulatory environments. Prior to its acquisition by Sanofi in 2011, the company reported through four primary business segments: Therapeutics, Renal, Transplant, and Biosurgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> The Therapeutics division concentrated on enzyme replacement and substrate reduction therapies for rare genetic disorders, including products such as Cerezyme for Gaucher disease (generating $733.8 million in revenue in 2003, representing 47% of total product revenue) and Fabrazyme for Fabry disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> The Renal division focused on treatments for chronic kidney disease, led by Renagel, a phosphate binder that accounted for $281.7 million in revenue (18% of product revenue) in 2003.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Transplant division developed immunosuppressive agents to prevent organ rejection and treat autoimmune conditions, with flagship products including Thymoglobulin and Lymphoglobuline.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Biosurgery targeted surgical and orthopedic applications through biotherapeutics and biomaterials, such as Synvisc for viscosupplementation in osteoarthritis and Seprafilm for reducing postoperative adhesions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Additionally, Genzyme operated a Diagnostics segment providing genetic testing services and diagnostic products, though it contributed a smaller share of overall revenue. This structure evolved from earlier configurations, including the discontinuation of standalone Genzyme General and Genzyme Molecular Oncology divisions by mid-2003, consolidating operations under unified financial reporting while retaining therapeutic focus.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Following Sanofi&#x27;s $20.1 billion acquisition in June 2011, Genzyme&#x27;s rare disease operationsâ€”primarily the legacy Therapeutics segmentâ€”were preserved as a standalone division under the Sanofi Genzyme brand to maintain specialized expertise and brand continuity, with dedicated leadership and resources integrated into Sanofi&#x27;s broader portfolio.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Other segments, such as Renal-Endocrinology, Hematology-Oncology, and Biosurgery, were aligned with complementary Sanofi units to enhance synergies in distribution and R&amp;D.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> This hybrid model allowed Genzyme&#x27;s divisions to benefit from Sanofi&#x27;s global infrastructure while minimizing disruption to high-margin orphan drug operations, though full integration led to the phase-out of the Genzyme name for non-rare disease activities by 2022.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup></span>
<h3 id="manufacturing-and-supply-chain" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Manufacturing and Supply Chain<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Genzyme&#x27;s manufacturing operations centered on biologics production for rare disease therapies, with primary facilities in Massachusetts. The company&#x27;s flagship plant in Allston, Boston, served as a key site for producing enzyme replacement therapies like Cerezyme and Fabrazyme, undergoing expansion starting in September 2007 to meet growing demand.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> In 2013, Genzyme invested $80 million to expand capacity at its Framingham, Massachusetts facility specifically for Fabrazyme production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eeabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> Following the 2011 acquisition by Sanofi, Genzyme&#x27;s operations integrated into Sanofi&#x27;s global network, which included 17 manufacturing sites worldwide as of that period.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ieabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A significant disruption occurred in 2009 when viral contamination at the Allston facility halted production of Cerezyme and Fabrazyme. On March 2, 2009, the FDA issued a warning letter citing manufacturing deficiencies at the site, followed by detection of Vesivirus 2117 contamination on June 16, 2009, prompting a shutdown for cleaning and remediation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> This led to global shortages of these critical drugs, with analysts estimating revenue losses of $100â€“300 million in 2009 alone, and prolonged supply constraints for Fabrazyme into 2012.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> In May 2010, Genzyme agreed to surrender $175 million to resolve FDA charges of inadequate quality systems during inspections from September 2009 to November 2009.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> The Allston plant was later leased to National Resilience in 2021.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_keqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme&#x27;s supply chain relied heavily on these specialized facilities, exposing vulnerabilities to single-site failures, as evidenced by the 2009 crisis and subsequent litigation over Fabrazyme shortages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> To mitigate risks, the company pursued diversified production strategies across multiple sites.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> Post-acquisition, Sanofi enhanced capabilities with continuous biologics manufacturing at Framingham, one of the first digitally enabled facilities of its kind.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> However, challenges persisted; in January 2025, the FDA issued a warning letter to Sanofi for bioreactor irregularities at the Framingham Genzyme plant, though the company stated the supply chain remained unaffected.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ifabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Sanofi Genzyme continues to focus on resilience in its complex global supply chain for rare disease products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup></span>
<h3 id="global-reach-and-workforce" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Global Reach and Workforce<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme began its international expansion in the mid-1980s to support growing demand for its diagnostic and therapeutic products. In 1986, the company established a subsidiary in Japan, financed through local sales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> This was followed in 1988 by the opening of a pharmaceutical chemical manufacturing plant in Haverhill, United Kingdom.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> By 1991, Genzyme had formed Genzyme B.V., a European subsidiary in Naarden, Netherlands, with ongoing operations in the Netherlands, Japan, and England.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The company further developed its global manufacturing capabilities, including a major campus in Waterford, Ireland, operational by 2003 for solid-dose production of Renagel tablets and later expanded for biologics fill-finish processes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> This site employed 370 workers by the end of 2006 and grew to over 600 by 2008 after â‚¬150 million in additional investment, contributing to cumulative spending exceeding â‚¬410 million by 2010.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> By the late 2000s, Genzyme maintained over 70 locations across 30 countries to facilitate product development, manufacturing, and distribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme&#x27;s workforce expanded alongside its footprint, reaching more than 12,000 employees worldwide by 2010, supporting operations from research to patient delivery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> After Sanofi&#x27;s 2011 acquisition, Genzyme&#x27;s activities integrated into the parent company&#x27;s network, which operates in over 100 countries and leverages specialized sites for rare disease therapies, including facilities in Framingham, Massachusetts; Waterford, Ireland; and Haverhill, United Kingdom.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> This structure sustains Genzyme&#x27;s capacity to reach patients in nearly 100 countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ehabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<h2 id="products-and-therapeutic-focus" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Products and Therapeutic Focus<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="rare-disease-therapies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Rare Disease Therapies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme specialized in enzyme replacement therapies (ERTs) for lysosomal storage disorders, a group of rare inherited metabolic diseases resulting from genetic deficiencies in enzymes that degrade cellular waste, leading to substrate accumulation and organ damage. These therapies, administered intravenously, supply functional recombinant enzymes to mitigate symptoms such as organomegaly, skeletal abnormalities, and neurological impairment. By targeting orphan indications with small patient populations, Genzyme leveraged regulatory incentives like the U.S. Orphan Drug Act to develop products that addressed unmet needs in diseases affecting fewer than 200,000 Americans per condition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The company&#x27;s pioneering ERT for Gaucher disease, Cerezyme (imiglucerase), was approved by the FDA on May 23, 1994, as a long-term treatment for type 1 (non-neuronopathic) Gaucher disease. Cerezyme, a recombinant analog of Î²-glucocerebrosidase produced in Chinese hamster ovary cells, catalyzes the hydrolysis of glucocerebroside accumulated in macrophages, reducing liver and spleen volume, improving anemia, and enhancing bone health in clinical trials involving over 1,000 patients. This followed the 1991 approval of Ceredase (alglucerase), derived from purified human placental glucocerebrosidase, which treated approximately 4,000 patients before supply limitations prompted the shift to recombinant production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Fabrazyme (agalsidase beta), approved by the FDA on April 24, 2003, provides ERT for Fabry disease, an X-linked disorder caused by Î±-galactosidase A deficiency leading to globotriaosylceramide (GL-3) buildup in vascular endothelium and other tissues. The recombinant human enzyme, dosed at 1 mg/kg biweekly, clears GL-3 inclusions from kidney interstitial capillaries, as demonstrated in phase 3 trials showing histologic improvements and reduced pain in 58 adult males. Long-term data from open-label extensions confirm sustained GL-3 clearance and stabilization of renal function in patients treated for up to 10 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For Pompe disease (glycogen storage disease type II), Genzyme&#x27;s Myozyme (alglucosidase alfa) received FDA approval on April 28, 2006, initially for infantile-onset forms characterized by rapid cardiomegaly and hypotonia due to acid Î±-glucosidase (GAA) deficiency. The recombinant human GAA, produced in Chinese hamster ovary cells, promotes glycogen breakdown in lysosomes, improving ventilator-free survival and cardiac function in pivotal trials of 21 infants, where 72% survived beyond 18 months compared to historical controls. Manufacturing scale-up led to Lumizyme approval in 2010 for late-onset Pompe, expanding access without age restrictions based on bioequivalence data and registry outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme also marketed Aldurazyme (laronidase) for mucopolysaccharidosis type I (MPS I), co-developed with BioMarin and approved by the FDA in March 2003 for Hurler and Hurler-Scheie syndromes. This ERT delivers recombinant Î±-L-iduronidase to degrade accumulated glycosaminoglycans, reducing urinary excretion by 60-70% and improving forced vital capacity in clinical studies of 45 patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Product</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Indication</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">FDA Approval Date</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Key Mechanism</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Cerezyme</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Type 1 Gaucher disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">May 23, 1994</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Recombinant Î²-glucocerebrosidase hydrolyzes glucocerebroside</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18clabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fabrazyme</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fabry disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">April 24, 2003</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Recombinant Î±-galactosidase A clears GL-3 deposits</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18klabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Myozyme/Lumizyme</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Pompe disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">April 28, 2006</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Recombinant acid Î±-glucosidase degrades lysosomal glycogen</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18slabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Aldurazyme</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">MPS I (Hurler/Hurler-Scheie)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">March 2003</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Recombinant Î±-L-iduronidase breaks down glycosaminoglycans</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_194labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></td></tr></tbody></table></div>
<h3 id="other-biotech-products" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Other Biotech Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme developed a range of biotechnology products targeting conditions with higher prevalence than rare genetic disorders, including osteoarthritis, cartilage defects, and thyroid cancer monitoring, through its biosurgery and diagnostics divisions. These products diversified the company&#x27;s portfolio beyond enzyme replacement therapies, leveraging recombinant proteins, cell-based therapies, and biopolymers derived from natural sources.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Synvisc (hylan G-F 20), a cross-linked hyaluronan viscosupplement derived from rooster combs, was approved by the U.S. Food and Drug Administration (FDA) on August 4, 1997, for intra-articular injection to relieve pain in patients with osteoarthritis of the knee who had not responded to conservative non-pharmacological therapy or simple analgesics. The product chemically modifies hyaluronic acid to provide extended joint lubrication and shock absorption, mimicking natural synovial fluid, with a single-dose variant, Synvisc-One, later introduced for convenience. Clinical trials demonstrated statistically significant pain reduction lasting up to six months post-injection compared to placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Renagel (sevelamer hydrochloride), a non-calcium, non-aluminum phosphate-binding polymer, received FDA approval on October 7, 2000, for controlling serum phosphorus levels in chronic kidney disease patients on hemodialysis, addressing hyperphosphatemia to prevent complications like vascular calcification. Unlike traditional binders, it avoids metal ions, reducing risks of aluminum toxicity or hypercalcemia; phase III trials showed equivalent phosphorus control to calcium-based agents with lower calcium-phosphate product levels. The product contributed substantially to revenue, generating $515 million in 2006 amid growing dialysis populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Carticel (autologous cultured chondrocytes), the first FDA-approved cell therapy for orthopedic use on August 16, 1997, treated symptomatic full-thickness chondral defects of the knee in patients aged 18-55 via periosteal grafting and implantation of expanded autologous cartilage cells to promote tissue regeneration. The process involved harvesting chondrocytes from the patient, culturing them ex vivo, and reimplanting, with long-term studies indicating improved defect filling and function over microfracture alone. This represented an early advance in regenerative medicine for non-rare joint conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Thyrogen (thyrotropin alfa), a recombinant human thyroid-stimulating hormone produced in Chinese hamster ovary cells, was approved by the FDA on December 23, 1998, as an adjunct for serum thyroglobulin testing and radioiodine ablation in thyroid cancer patients to detect recurrence without inducing hypothyroidism. It enables TSH elevation without thyroid hormone withdrawal, shortening diagnostic preparation time from 4-6 weeks to 1-2 days; pivotal trials confirmed comparable sensitivity to withdrawal methods for thyroglobulin measurement. Annual U.S. sales reached approximately $100 million by the mid-2000s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<h3 id="research-and-development-pipeline" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Research and Development Pipeline<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sanofi&#x27;s integration of Genzyme has sustained and expanded research into lysosomal storage disorders (LSDs) and other rare diseases, with a pipeline emphasizing enzyme replacement therapies, substrate reduction approaches, and gene-based interventions as of September 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> This builds on Genzyme&#x27;s historical leadership in LSD treatments, such as Cerezyme for Gaucher disease, by advancing next-generation modalities to address unmet needs like neurological manifestations and earlier disease intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> The rare diseases segment includes approximately 10-15 clinical-stage projects, with several in phase 3 targeting LSDs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Project/Agent</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Target Disease</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Phase</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Modality/Key Details</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Venglustat</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fabry disease; Gaucher disease type 3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Phase 3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Oral glucosylceramide synthase (GCS) inhibitor for substrate reduction; ongoing trials (e.g., PERIDOT, CARAT) evaluate long-term efficacy in renal and neurological symptoms.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18cpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1ocpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Nexviazyme (avalglucosidase alfa)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Infantile-onset Pompe disease</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Phase 3 (extensions)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Next-generation enzyme replacement therapy; approved for late-onset but investigational expansions for infantile forms focus on improved uptake and sustained glycogen reduction.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18kpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1okpqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Cerezyme (imiglucerase)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Gaucher disease type 3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Investigational (post-approval)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Enzyme replacement therapy; approved for type 1 since 1994, current evaluations target type 3 for neurological involvement in U.S. patients.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18spqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1ospqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Efdoralprin alfa</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Alpha-1 antitrypsin deficiency (AATD)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Phase 1-3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">AAT fusion protein to enhance lung protection; addresses emphysema in this genetic disorder.</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_194pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1p4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond LSDs, the pipeline incorporates Genzyme-aligned innovations in rare blood and neuromuscular disorders, such as rilzabrutinib (phase 3 for focal segmental glomerulosclerosis/minimal change disease) and gene editing for sickle cell disease, leveraging technologies like AAV-mediated siRNA and BTK inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> These efforts prioritize small patient populations through patient registries, AI-driven insights, and collaborations, with recent data from 2025 presentations underscoring potential disease-modifying effects in hemophilia and immune thrombocytopenia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Sanofi reported three rare diseases-related regulatory milestones in Q2 2025, reflecting pipeline momentum despite challenges in earlier-stage attrition.</span>
<h2 id="innovations-and-achievements" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Innovations and Achievements<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pioneering-orphan-drug-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pioneering Orphan Drug Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme Corporation pioneered the commercial development of orphan drugs by targeting rare genetic disorders, particularly lysosomal storage diseases, in an era when such markets were overlooked by larger pharmaceutical firms due to limited patient numbers and high development costs. Founded in 1981 and led by CEO Henri Termeer from 1985, the company capitalized on the U.S. Orphan Drug Act of 1983, which granted seven years of market exclusivity, tax credits, and regulatory incentives to offset the economic risks of treating conditions affecting fewer than 200,000 Americans. This approach demonstrated that biologics for ultra-rare diseases could achieve profitability through premium pricing justified by the absence of alternatives and the complexity of production, thereby establishing a viable business model for the sector.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A landmark achievement was the 1991 FDA approval of Ceredase (alglucerase), Genzyme&#x27;s first orphan drug and the initial enzyme replacement therapy (ERT) for type 1 Gaucher disease, a disorder caused by glucocerebrosidase deficiency leading to organ enlargement and bone damage in roughly 6,000 U.S. patients. Harvested from human placental tissue, Ceredase required purification from up to 20,000 placentas per year to meet demand, highlighting the logistical innovations Genzyme implemented to scale supply for small cohorts. The drug&#x27;s exclusivity under the Orphan Drug Act enabled recoupment of development expenses, with sales reaching $100 million annually by the mid-1990s despite the niche indication.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme advanced this model in 1994 with Cerezyme (imiglucerase), a recombinant ERT manufactured using Chinese hamster ovary cells, which eliminated reliance on human-derived materials and improved purity and yield. Clinical data confirmed Cerezyme&#x27;s noninferiority to Ceredase in restoring enzyme activity and alleviating symptoms, facilitating a seamless transition that sustained therapy access while reducing immunogenicity risks. This recombinant shift exemplified Genzyme&#x27;s commitment to biotechnological refinement, paving the way for further orphan approvals like Fabrazyme (agalsidase beta) for Fabry disease in 2003 and Myozyme (alglucosidase alfa) for Pompe disease in 2006, each addressing unmet needs in substrate accumulation disorders through targeted ERT.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By prioritizing patient registries, long-term outcome studies, and advocacy for regulatory flexibility, Genzyme under Termeer not only treated thousands but also influenced industry norms, proving that orphan drug investment could yield sustainable returnsâ€”exceeding $1 billion in annual revenue from its rare disease portfolio by 2010â€”while spurring competitors to enter the field and expanding treatment options for conditions previously managed palliatively.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<h3 id="economic-and-medical-impact" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Economic and Medical Impact<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme&#x27;s orphan drug strategy yielded significant economic returns, with revenues totaling $4.1 billion in 2010, driven largely by high-margin therapies for rare diseases that benefited from limited competition and regulatory incentives under the Orphan Drug Act.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> This model supported a global workforce of approximately 10,000 employees engaged in research, manufacturing, and commercialization, concentrating economic activity in biotechnology hubs such as Boston, Massachusetts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The approach validated the viability of investing in small patient populations, encouraging broader sector shifts toward rare disease-focused development and culminating in Genzyme&#x27;s $20.1 billion acquisition by Sanofi in 2011, which enhanced Sanofi&#x27;s specialty care portfolio and contributed to a 6.9% sales growth in the following year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_euabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On the medical front, Genzyme&#x27;s enzyme replacement therapies (ERTs) profoundly altered outcomes for patients with lysosomal storage disorders, conditions previously marked by progressive organ failure and early mortality. Imiglucerase (Cerezyme), approved in 1994 for type 1 Gaucher disease, reversed key pathologies including hepatosplenomegaly, anemia, thrombocytopenia, and skeletal deterioration, with long-term studies showing sustained reductions in bone pain, crises, and disease-related complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Similarly, agalsidase beta (Fabrazyme) for Fabry disease and alglucosidase alfa (Myozyme/Lumizyme) for Pompe disease mitigated cardiac, renal, and neuromuscular damage, extending survival and improving functional status in clinical cohorts where supportive care alone yielded poor prognoses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup> These interventions established ERT as a cornerstone for managing enzyme deficiencies, enabling affected individualsâ€”often numbering in the hundreds or thousands worldwide per disorderâ€”to achieve stable health metrics absent prior therapeutic options.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_euqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<h3 id="strategic-acquisitions-and-partnerships" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Strategic Acquisitions and Partnerships<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme strategically acquired smaller biotechnology firms to address manufacturing bottlenecks and broaden its therapeutic portfolio in rare diseases and oncology. In September 2001, it completed the acquisition of Novazyme Pharmaceuticals for $137.5 million payable in Genzyme stock, with potential additional payments of up to $87.5 million contingent on regulatory milestones for enzyme replacement therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Novazyme&#x27;s proprietary gene activation and ProCellEx plant cell expression technologies enabled Genzyme to achieve higher yields of recombinant enzymes, mitigating supply shortages for Cerezyme (imiglucerase) used in Gaucher disease treatment and facilitating the 2006 FDA approval of Myozyme (alglucosidase alfa) for Pompe disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> This move was particularly timely, as Genzyme faced production constraints from viral contamination incidents in its Allston, Massachusetts facility earlier that year.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2009, Genzyme diversified into oncology through the acquisition of Bayer HealthCare&#x27;s portfolio of marketed oncology products, including Campath (alemtuzumab), a monoclonal antibody approved for B-cell chronic lymphocytic leukemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> The deal, valued at approximately $225 million plus royalties, allowed Genzyme to leverage its rare disease sales infrastructure for these specialized cancer therapies, generating over $100 million in annual Campath sales by 2010 while assuming Bayer&#x27;s prior manufacturing and royalty obligations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme also pursued partnerships to access cutting-edge platforms in antisense and gene modulation technologies, accelerating pipeline development without full internal R&amp;D investment. In January 2008, it formed a strategic alliance with Isis Pharmaceuticals (now Ionis), securing exclusive worldwide rights to develop and commercialize mipomersen, an antisense drug targeting apoB to lower LDL cholesterol in high-risk cardiovascular patients, with an upfront payment of $175 million, $150 million in near-term R&amp;D funding, and potential milestones and royalties exceeding $1 billion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> Phase III trials under this collaboration advanced mipomersen toward FDA review, though regulatory hurdles later emerged. Complementing this, Genzyme maintained ongoing collaborations with PTC Therapeutics on small-molecule splicing modifiers for rare genetic conditions like spinal muscular atrophy, initiated in the mid-2000s and restructured in 2011 to focus on lead candidates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> These alliances underscored Genzyme&#x27;s approach to risk-sharing in high-cost biotech innovation, prioritizing orphan indications with limited competition.</span>
<h2 id="controversies-and-criticisms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Controversies and Criticisms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="manufacturing-contamination-and-product-shortages-2009-2011" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Manufacturing Contamination and Product Shortages (2009-2011)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">In February 2009, the U.S. Food and Drug Administration (FDA) issued a warning letter to Genzyme regarding manufacturing deficiencies at its Allston, Massachusetts facility, highlighting issues with quality control and production processes for biologic drugs including Cerezyme and Fabrazyme.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> These concerns predated the more severe disruptions that followed.</span>
<span class="mb-4 block break-words text-[1em] leading-7">On June 16, 2009, Genzyme disclosed the detection of Vesivirus 2117, a non-human virus, in bioreactors at the Allston plant, which impaired cell growth and necessitated a shutdown of production for Cerezyme (imiglucerase), an enzyme replacement therapy for Gaucher disease, and Fabrazyme (agalsidase beta), a treatment for Fabry disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> The contamination affected multiple production batches, leading to immediate global shortages of these orphan drugs, as the Allston facility was the primary manufacturing site.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Genzyme implemented dose rationing protocols, reducing patient allocations to 40-70% of standard levels to extend supplies, which impacted approximately 1,500 Cerezyme patients and fewer than 1,000 Fabrazyme patients worldwide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The shortages resulted in reported adverse health effects among patients, including chronic pain, fatigue, muscle spasms, and cognitive impairments; one Fabry patient, William Schubert, died in March 2010 amid reduced dosing, though a direct causal link was not established.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Genzyme&#x27;s CEO Henri Termeer acknowledged the company&#x27;s failure to maintain adequate reserves, attributing it partly to prioritization of production for Myozyme, a therapy for Pompe disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Efforts to mitigate the crisis included accelerating production at alternative sites and importing limited supplies, with initial shipments of new Cerezyme resuming in December 2009 and Fabrazyme in January 2010, though at reduced volumes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A subsequent FDA inspection from October to November 2009 uncovered additional violations, including particulate contaminationâ€”such as metal fragments, rubber, fibers, and glassâ€”in finished vials of Cerezyme, Fabrazyme, Myozyme, and Thyrogen, stemming from inadequate equipment maintenance and inspection processes in the aseptic filling operations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> The agency issued Form 483 observations citing failures in deviation investigations and preventive measures, prompting Genzyme to discard affected batches.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory pressure intensified in 2010, culminating in a May consent decree requiring Genzyme to pay a $175 million penalty, outsource filling and packaging, and implement FDA oversight at Allston; violations risked further shutdowns.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> Despite these measures and production transfers to facilities in Ireland and Kansas by late 2010, shortages persisted into 2011, with limited Cerezyme supplies projected through January 2012 due to ongoing capacity constraints and quality issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup> The crisis contributed to a decline in Genzyme&#x27;s revenue and stock value, exacerbating vulnerabilities ahead of its acquisition by Sanofi-Aventis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<h3 id="marketing-practices-and-legal-settlements" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Marketing Practices and Legal Settlements<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2013, Genzyme Corporation agreed to pay $22.28 million to settle civil allegations under the False Claims Act that it promoted an unapproved &quot;slurry&quot; form of its Seprafilm adhesion barrier product, leading to the submission of false claims to federal and state healthcare programs for off-label uses not approved by the FDA.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> The settlement stemmed from whistleblower complaints alleging that Genzyme sales representatives distributed recipes and training materials to physicians on converting solid Seprafilm sheets into a liquid slurry for intra-abdominal applications, despite the product&#x27;s labeling restricting it to solid-sheet use on serosal surfaces during surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> This practice allegedly occurred between 2004 and 2009, with the company cooperating in the federal investigation but denying liability as part of the resolution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Seprafilm controversy escalated in 2015 when Genzyme entered a deferred prosecution agreement with the U.S. Department of Justice, agreeing to pay an additional $32.5 million to resolve criminal charges related to the same off-label promotion and distribution of the slurry form.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup> Under the agreement, Genzyme admitted that its employees had engaged in a scheme to promote the unapproved slurry despite internal policies prohibiting off-label promotion, including disseminating non-public information and materials to encourage its use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup> The total penalties for the Seprafilm marketing issues exceeded $54 million, including state-level recoveries such as New Jersey&#x27;s $102,000 share from alleged kickback schemes tied to the promotion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> These settlements highlighted compliance risks in promoting medical devices beyond FDA-approved indications, though Genzyme implemented remedial measures like enhanced training and monitoring post-resolution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">No major additional settlements directly tied to off-label marketing of Genzyme&#x27;s other products, such as its rare disease therapies, were identified in public records from the period, though the company faced broader scrutiny over sales practices amid its high pricing for orphan drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> The Seprafilm cases were resolved without criminal charges against individuals, reflecting a focus on corporate accountability through monetary penalties and deferred prosecution rather than trial outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<h3 id="patient-safety-and-dosage-disputes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Patient Safety and Dosage Disputes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In response to manufacturing shortages of Fabrazyme (agalsidase beta), the enzyme replacement therapy for Fabry disease, the U.S. Food and Drug Administration (FDA) authorized reduced dosages starting in June 2010, initially at one-third of the standard 1 mg/kg biweekly dose, later increased to half in some cases, to extend limited supplies amid production issues at Genzyme&#x27;s Allston, Massachusetts facility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> Genzyme implemented a rationing program allocating approximately 0.3â€“0.5 mg/kg per infusion, prioritizing existing patients while deferring new ones, with internal documents later revealing company awareness that such reductions might not maintain therapeutic efficacy against progressive kidney, heart, and neurological damage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Patient advocacy groups and affected individuals contested the safety of these lower doses, arguing they failed to stabilize disease progression, leading to documented deteriorations such as worsening renal function and increased pain, as evidenced in clinical monitoring data from rationed patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup> Multiple class-action lawsuits filed against Genzyme (later Sanofi post-2011 acquisition) alleged negligence in continuing reduced-dose distribution despite knowledge of inefficacy, with claims that the company diverted fuller supplies to Europe where shortages were less acute, potentially exacerbating U.S. patient harms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> A 2024 federal appeals court ruling revived key litigation, rejecting prior dismissals and allowing evidence on whether Genzyme misrepresented dose adequacy, though long-term studies on reduced dosing remain limited and contested, with some pharmacodynamic data suggesting partial benefit but not equivalence to full dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Similar dosage debates arose with Cerezyme (imiglucerase) for Gaucher disease, where in 2008, amid high annual costs exceeding $200,000 per patient at standard 60 units/kg thrice weekly, the National Gaucher Foundation endorsed dose reductions to 15â€“30 units/kg based on retrospective analyses showing maintained hemoglobin and platelet stability in low-risk patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_78qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> Genzyme countered that such cuts risked inadequate visceral and skeletal protection, citing phase III trial data establishing higher doses for optimal outcomes, though acknowledging no acute toxicity from reductions; unresolved questions persisted on minimal effective dosing, influenced by pharmacoeconomic pressures rather than definitive safety thresholds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> During 2009â€“2011 Cerezyme shortages, temporary dose tapering to every other week or lower amounts was again FDA-sanctioned, with post-shortage studies indicating transient biomarker worsening in some adults but no irreversible harms in monitored cohorts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These disputes highlighted tensions between resource allocation during supply constraints and evidence-based dosing, with critics attributing Genzyme&#x27;s stance to revenue preservationâ€”given orphan drug pricing dynamicsâ€”while company responses emphasized data-driven protocols to avert undertreatment risks, absent randomized trials conclusively proving low-dose equivalence for safety endpoints like organ preservation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup> No regulatory findings deemed standard doses unsafe, but litigation outcomes remain pending for Fabrazyme claims, underscoring ongoing scrutiny of biotech firms&#x27; handling of rare disease therapy access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup></span>
<h2 id="regulatory-engagement-and-lobbying" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Regulatory Engagement and Lobbying<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="interactions-with-fda-and-other-agencies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Interactions with FDA and Other Agencies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme Corporation&#x27;s interactions with the U.S. Food and Drug Administration (FDA) primarily involved securing orphan drug designations and biologic license applications for enzyme replacement therapies targeting rare genetic disorders, leveraging incentives under the Orphan Drug Act of 1983 such as protocol assistance, tax credits, and seven-year market exclusivity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> The FDA granted orphan designation for imiglucerase (Cerezyme) for Gaucher disease types I, II, and III, culminating in approval on May 23, 1994, marking Genzyme&#x27;s first major therapeutic for a lysosomal storage disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Similarly, agalsidase beta (Fabrazyme) received orphan designation in 1998 and FDA approval on April 24, 2003, for Fabry disease, while alglucosidase alfa (Myozyme) was designated and approved on April 28, 2006, for Pompe disease, with both latter products carrying boxed warnings for anaphylaxis and hypersensitivity risks common to such therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_daqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_faqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_haqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These approvals often followed priority or accelerated review pathways due to the orphan status and unmet needs in rare diseases, reflecting collaborative pre-approval consultations between Genzyme and FDA on clinical trial designs and manufacturing scales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Post-approval, interactions included FDA oversight of adverse event reporting and labeling updates, such as enhanced warnings for immune-mediated reactions in enzyme replacement therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory enforcement formed another key facet, particularly following FDA inspections of Genzyme&#x27;s Allston, Massachusetts, facility that identified current good manufacturing practice violations, including equipment contamination risks. On May 24, 2010, Genzyme signed a consent decree of permanent injunction with the FDA and Department of Justice, requiring a $175 million disgorgement of profits, submission of a detailed remediation timetable (initially proposed in October 2009), independent audits, and FDA approval for resuming full production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> By November 2010, Genzyme met initial milestones under the decree, including facility upgrades, though full compliance extended into subsequent years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond the FDA, Genzyme engaged with the European Medicines Agency (EMA) for parallel authorizations, such as Myozyme&#x27;s approval in March 2006 ahead of its U.S. counterpart, and EMA validation of the Framingham, Massachusetts, plant in January 2012 to support expanded supply.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> These multinational interactions underscored Genzyme&#x27;s navigation of harmonized standards under the International Conference on Harmonisation while addressing agency-specific requirements for orphan medicinal products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<h3 id="advocacy-on-intellectual-property-and-orphan-drug-policies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Advocacy on Intellectual Property and Orphan Drug Policies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme, under the leadership of CEO Henri Termeer, actively advocated for policies that bolstered incentives under the U.S. Orphan Drug Act of 1983, emphasizing the necessity of market exclusivity and tax credits to offset the high development costs for treatments of rare diseases affecting fewer than 200,000 individuals in the United States.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> The company&#x27;s flagship enzyme replacement therapies, such as Ceredase (approved in 1991) and its successor Cerezyme (approved in 1994), directly benefited from the Act&#x27;s seven-year market exclusivity provisions, which Genzyme defended as essential to recouping investments in niche markets with limited patient populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Termeer argued that without such protections, pharmaceutical firms would lack economic motivation to pursue orphan drug development, a stance he articulated in congressional testimony opposing proposed price caps on these therapies during the 1990s, when critics highlighted escalating costs like Cerezyme&#x27;s annual price exceeding $300,000 per patient.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In response to challenges threatening exclusivity, Genzyme resisted efforts to compel technology transfer or generic production during supply shortages, such as the 2009-2011 contamination crises affecting Cerezyme and Fabrazyme. Patients petitioned the National Institutes of Health in 2011 to intervene and mandate Genzyme share manufacturing processes with competitors, but the company maintained that undermining exclusivity would deter future innovation in rare disease treatments by eroding the financial viability of such endeavors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> This position aligned with broader industry lobbying to preserve the Orphan Drug Act&#x27;s framework against reforms aimed at curbing perceived abuses, including multiple orphan designations for the same drug across indications to extend effective exclusivity periods beyond seven yearsâ€”a strategy Genzyme employed but which drew scrutiny for potentially inflating prices without proportional public health benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On intellectual property fronts intertwined with orphan policies, Genzyme supported robust patent protections for biotechnological innovations, viewing them as complementary to regulatory exclusivities in sustaining R&amp;D for complex enzyme therapies. In European contexts, the company invoked protections under EU Regulation 141/2000, which grants 10-year orphan drug exclusivity, to defend against competitive challenges, as evidenced in a 2004 UK Competition Appeal Tribunal ruling acknowledging the specialized nature of orphan drug rights in limiting market entry.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> Termeer-era advocacy extended to international forums, promoting similar incentive structures globally to encourage neglected disease research, though Genzyme prioritized maintaining U.S. and EU safeguards amid growing debates over high pricing and access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> These efforts underscored Genzyme&#x27;s view that strong IP and orphan-specific policies were causally linked to the Act&#x27;s success in spurring over 2,000 orphan designations by the early 2010s, transforming previously untreatable conditions into manageable ones despite criticisms of monopolistic pricing dynamics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup></span>
<h2 id="post-acquisition-legacy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Post-Acquisition Legacy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="integration-into-sanofi" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Integration into Sanofi<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Sanofi completed its acquisition of Genzyme on April 8, 2011, following shareholder approval and regulatory clearances, for a total enterprise value of approximately $20.1 billion, or $74 per share in cash.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Immediately after the February 2011 announcement, the companies formed a joint Integration Steering Committee to oversee the process, focusing on operational alignment while preserving Genzyme&#x27;s biotechnology expertise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bfqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Genzyme&#x27;s rare disease business was initially structured as a stand-alone division within Sanofi, retaining the Genzyme brand to maintain continuity in its specialized operations and patient-focused model.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ffqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By mid-2011, Sanofi implemented changes to integrate Genzyme&#x27;s functions, including a new reporting structure for marketing and sales units and coordination of R&amp;D programs under an umbrella Sanofi Oncology unit to leverage synergies in biotechnology and therapeutic development.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> Sanofi&#x27;s leadership described the 2011 integration as successful, noting contributions to overall revenue growth from Genzyme&#x27;s platforms in rare diseases and multiple sclerosis treatments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> This phase emphasized retaining Genzyme&#x27;s autonomous operations in key areas, such as its Framingham, Massachusetts headquarters, to avoid disrupting ongoing clinical and manufacturing activities amid prior contamination issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In July 2015, Sanofi reorganized its global business units, establishing the Specialty Care Global Business Unit as &quot;Sanofi Genzyme,&quot; led by David Meeker, former Genzyme president, encompassing rare diseases, multiple sclerosis, immunology, and oncology portfolios to drive focused growth in high-value therapeutics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> This structure integrated Genzyme&#x27;s assets more deeply into Sanofi&#x27;s specialty care strategy, combining them with complementary products like multiple sclerosis drug Aubagio while maintaining dedicated rare disease expertise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By February 2022, Sanofi completed full integration of the Sanofi Genzyme entity into its broader Specialty Care division, discontinuing the separate Genzyme branding after 11 years to streamline operations and unify its rare disease and specialty portfolio under a single corporate identity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> This culminated the multi-year integration, with Genzyme&#x27;s legacy productsâ€”such as Cerezyme for Gaucher disease and Fabrazyme for Fabry diseaseâ€”continuing under Sanofi&#x27;s oversight, contributing to sustained revenue from orphan drugs exceeding expectations set at acquisition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> Post-2022, no major structural reversals occurred, with the integrated unit supporting Sanofi&#x27;s emphasis on biologics and gene therapies through 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup></span>
<h3 id="ongoing-influence-and-recent-developments-2011-2025" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Ongoing Influence and Recent Developments (2011-2025)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following its acquisition by Sanofi on April 8, 2011, Genzyme&#x27;s rare disease franchises drove substantial revenue growth for the parent company, with integration efforts yielding double-digit expansion in growth platforms by 2012.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> The deal positioned Genzyme as a core biotechnology pillar, enhancing Sanofi&#x27;s capabilities in enzyme replacement therapies and orphan drugs while addressing prior manufacturing vulnerabilities through combined resources.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Genzyme operated initially as a semi-autonomous unit under its brand, preserving operational continuity in treatments for lysosomal storage disorders such as Gaucher disease (Cerezyme) and Fabry disease (Fabrazyme), which continued to generate sustained sales amid resolved supply chain issues from pre-acquisition shortages.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> This structure facilitated R&amp;D acceleration, including biomarker-driven expansions for legacy assets like Campath (alemtuzumab), repurposed for specific patient subsets post-merger.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By 2022, Sanofi phased out the Genzyme name from its specialty care division after 11 years, signaling full strategic integration while maintaining the underlying portfolio&#x27;s influence on rare disease strategy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> The legacy endures through Sanofi&#x27;s ongoing commercialization of Genzyme-originated therapies, including approvals and expansions for Pompe disease (Myozyme/Lumizyme) and mucopolysaccharidosis I (Aldurazyme), which remain foundational to the company&#x27;s rare disease revenue exceeding expectations set at acquisition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent advancements build on this foundation, with Sanofi leveraging Genzyme&#x27;s expertise in 2020 via the Principia Biopharma acquisition to extend into immune-mediated rare blood disorders like chronic immune thrombocytopenia, incorporating targeted oral therapies alongside traditional enzyme replacements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup> As of 2025, the rare diseases pipelineâ€”encompassing 86 projects across immunology, neurology, and oncology intersectionsâ€”incorporates RNAi therapeutics and nanobody platforms to address unmet needs in hemophilia and other inherited disorders, reflecting evolved causal mechanisms from Genzyme&#x27;s enzyme-focused origins.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> Sanofi&#x27;s rilzabrutinib, advancing for rare autoimmune conditions, exemplifies this progression toward manageable chronic diseases, with real-world data underscoring persistent efficacy of integrated legacy products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.reuters.com/article/2011/02/16/sanofi-genzyme-facts-idUSLDE71F0HY20110216/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/article/2011/02/16/sanofi-genzyme-facts-idUSLDE71F0HY20110216/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/article/2011/02/16/sanofi-genzyme-facts-idUSLDE71F0HY20110216/</a></span></div></li><li id="https://nationalmedals.org/laureate/genzyme-incorporated/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nationalmedals.org/laureate/genzyme-incorporated/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nationalmedals.org/laureate/genzyme-incorporated/</a></span></div></li><li id="https://www.statnews.com/sponsor/2020/01/30/building-on-a-legacy-of-enzyme-replacement-therapy-to-fuel-rare-disease-treatment/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/sponsor/2020/01/30/building-on-a-legacy-of-enzyme-replacement-therapy-to-fuel-rare-disease-treatment/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/sponsor/2020/01/30/building-on-a-legacy-of-enzyme-replacement-therapy-to-fuel-rare-disease-treatment/</a></span></div></li><li id="https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html</a></span></div></li><li id="https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/</a></span></div></li><li id="https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry</a></span></div></li><li id="https://now.tufts.edu/2012/04/12/flair-business-medicine" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://now.tufts.edu/2012/04/12/flair-business-medicine" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://now.tufts.edu/2012/04/12/flair-business-medicine</a></span></div></li><li id="https://www.news.sanofi.us/press-releases?item=118549" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news.sanofi.us/press-releases?item=118549" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news.sanofi.us/press-releases?item=118549</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/</a></span></div></li><li id="https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/</a></span></div></li><li id="https://caselaw.findlaw.com/court/us-1st-circuit/115829215.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://caselaw.findlaw.com/court/us-1st-circuit/115829215.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://caselaw.findlaw.com/court/us-1st-circuit/115829215.html</a></span></div></li><li id="https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/</a></span></div></li><li id="https://www.company-histories.com/Genzyme-Corporation-Company-History.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.company-histories.com/Genzyme-Corporation-Company-History.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.company-histories.com/Genzyme-Corporation-Company-History.html</a></span></div></li><li id="https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=5585" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=5585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=5585</a></span></div></li><li id="https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf</a></span></div></li><li id="https://purplebooksearch.fda.gov/productdetails?query=020367" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://purplebooksearch.fda.gov/productdetails?query=020367" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://purplebooksearch.fda.gov/productdetails?query=020367</a></span></div></li><li id="https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant</a></span></div></li><li id="https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/</a></span></div></li><li id="https://www.bioworld.com/articles/396653-genzyme-reports-profits-of-14m-for-1994" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bioworld.com/articles/396653-genzyme-reports-profits-of-14m-for-1994" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bioworld.com/articles/396653-genzyme-reports-profits-of-14m-for-1994</a></span></div></li><li id="https://www.nature.com/articles/nbt0596-572a.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nbt0596-572a.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nbt0596-572a.pdf</a></span></div></li><li id="https://www.bioworld.com/articles/364972-fda-approves-genzyme-s-carticel-for-cartilage-repair" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bioworld.com/articles/364972-fda-approves-genzyme-s-carticel-for-cartilage-repair" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bioworld.com/articles/364972-fda-approves-genzyme-s-carticel-for-cartilage-repair</a></span></div></li><li id="https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/</a></span></div></li><li id="https://biopharmguy.com/links/company-by-name-acquisitions.php" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://biopharmguy.com/links/company-by-name-acquisitions.php" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://biopharmguy.com/links/company-by-name-acquisitions.php</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/vprr/0505/05050784.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/vprr/0505/05050784.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/vprr/0505/05050784.pdf</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/732485/000110465907001467/a07-1497_1ex99d1.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/732485/000110465907001467/a07-1497_1ex99d1.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/732485/000110465907001467/a07-1497_1ex99d1.htm</a></span></div></li><li id="https://www.fiercebiotech.com/biotech/genzyme-reports-financial-results-for-second-quarter-of-2010" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercebiotech.com/biotech/genzyme-reports-financial-results-for-second-quarter-of-2010" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercebiotech.com/biotech/genzyme-reports-financial-results-for-second-quarter-of-2010</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm</a></span></div></li><li id="https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/</a></span></div></li><li id="https://www.nytimes.com/2009/06/17/business/17drug.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nytimes.com/2009/06/17/business/17drug.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nytimes.com/2009/06/17/business/17drug.html</a></span></div></li><li id="https://www.fiercepharma.com/pharma/genzyme-corp-signs-consent-decree-to-correct-violations-at-allston-mass-manufacturing-plant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/genzyme-corp-signs-consent-decree-to-correct-violations-at-allston-mass-manufacturing-plant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/genzyme-corp-signs-consent-decree-to-correct-violations-at-allston-mass-manufacturing-plant</a></span></div></li><li id="https://www.soci.org/chemistry-and-industry/cni-data/2010/9/genzyme-faces-175m-fda-fines" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.soci.org/chemistry-and-industry/cni-data/2010/9/genzyme-faces-175m-fda-fines" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.soci.org/chemistry-and-industry/cni-data/2010/9/genzyme-faces-175m-fda-fines</a></span></div></li><li id="https://www.cram.com/essay/Analysis-Of-Enzyme-Corporation/PKHMCUAZ7BQQ" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cram.com/essay/Analysis-Of-Enzyme-Corporation/PKHMCUAZ7BQQ" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cram.com/essay/Analysis-Of-Enzyme-Corporation/PKHMCUAZ7BQQ</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm</a></span></div></li><li id="https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/</a></span></div></li><li id="https://www.fiercepharma.com/manufacturing/sanofi-genzyme-deal-makes-consent-decree-a-mere-detail" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/manufacturing/sanofi-genzyme-deal-makes-consent-decree-a-mere-detail" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/manufacturing/sanofi-genzyme-deal-makes-consent-decree-a-mere-detail</a></span></div></li><li id="https://ec.europa.eu/competition/mergers/cases/decisions/m5999_20110112_20310_2550120_EN.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ec.europa.eu/competition/mergers/cases/decisions/m5999_20110112_20310_2550120_EN.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ec.europa.eu/competition/mergers/cases/decisions/m5999_20110112_20310_2550120_EN.pdf</a></span></div></li><li id="https://www.fiercepharma.com/pharma/sanofi-aventis-completes-acquisition-of-genzyme-corporation" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/sanofi-aventis-completes-acquisition-of-genzyme-corporation" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/sanofi-aventis-completes-acquisition-of-genzyme-corporation</a></span></div></li><li id="https://www.europeanpharmaceuticalreview.com/news/6539/sanofi-aventis-completes-acquisition-of-genzyme-corporation/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.europeanpharmaceuticalreview.com/news/6539/sanofi-aventis-completes-acquisition-of-genzyme-corporation/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.europeanpharmaceuticalreview.com/news/6539/sanofi-aventis-completes-acquisition-of-genzyme-corporation/</a></span></div></li><li id="https://www.npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion</a></span></div></li><li id="https://www.prnewswire.com/news-releases/sanofi-aventis-to-acquire-genzyme-for-7400-in-cash-per-share-plus-contingent-value-right-116291094.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/sanofi-aventis-to-acquire-genzyme-for-7400-in-cash-per-share-plus-contingent-value-right-116291094.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/sanofi-aventis-to-acquire-genzyme-for-7400-in-cash-per-share-plus-contingent-value-right-116291094.html</a></span></div></li><li id="https://www.fiercebiotech.com/biotech/sanofi-aventis-to-acquire-genzyme-for-74-00-cash-per-share-plus-contingent-value-right" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercebiotech.com/biotech/sanofi-aventis-to-acquire-genzyme-for-74-00-cash-per-share-plus-contingent-value-right" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercebiotech.com/biotech/sanofi-aventis-to-acquire-genzyme-for-74-00-cash-per-share-plus-contingent-value-right</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm</a></span></div></li><li id="https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/</a></span></div></li><li id="https://www.fiercepharma.com/manufacturing/genzyme-to-invest-80-million-framingham-mass-site-to-expand-manufacturing-capacity" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/manufacturing/genzyme-to-invest-80-million-framingham-mass-site-to-expand-manufacturing-capacity" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/manufacturing/genzyme-to-invest-80-million-framingham-mass-site-to-expand-manufacturing-capacity</a></span></div></li><li id="https://www.sanofi.com/en/our-science/manufacturing-and-supply" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/en/our-science/manufacturing-and-supply" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/en/our-science/manufacturing-and-supply</a></span></div></li><li id="https://www.nature.com/articles/nbt0809-681a" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nbt0809-681a" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nbt0809-681a</a></span></div></li><li id="https://www.biospace.com/genzyme-corporation-surrenders-175-million-for-violations-at-mass-facility" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/genzyme-corporation-surrenders-175-million-for-violations-at-mass-facility" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/genzyme-corporation-surrenders-175-million-for-violations-at-mass-facility</a></span></div></li><li id="https://news.harvard.edu/gazette/story/2021/03/national-resilience-takes-over-genzyme-sanofi-building-in-allston/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.harvard.edu/gazette/story/2021/03/national-resilience-takes-over-genzyme-sanofi-building-in-allston/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.harvard.edu/gazette/story/2021/03/national-resilience-takes-over-genzyme-sanofi-building-in-allston/</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118115800.ch4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118115800.ch4" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118115800.ch4</a></span></div></li><li id="https://www.dermatologyadvisor.com/news/fda-warns-sanofi-of-manufacturing-irregularities-at-key-facility/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dermatologyadvisor.com/news/fda-warns-sanofi-of-manufacturing-irregularities-at-key-facility/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dermatologyadvisor.com/news/fda-warns-sanofi-of-manufacturing-irregularities-at-key-facility/</a></span></div></li><li id="https://www.pharmamanufacturing.com/industry-news/news/55262524/sanofi-gets-fda-warning-letter-for-genzyme-plant-supply-chain-remains-unaffected" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmamanufacturing.com/industry-news/news/55262524/sanofi-gets-fda-warning-letter-for-genzyme-plant-supply-chain-remains-unaffected" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmamanufacturing.com/industry-news/news/55262524/sanofi-gets-fda-warning-letter-for-genzyme-plant-supply-chain-remains-unaffected</a></span></div></li><li id="https://www.aboutresilience.com/resilience-strategies-for-complex-supply-chains/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aboutresilience.com/resilience-strategies-for-complex-supply-chains/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aboutresilience.com/resilience-strategies-for-complex-supply-chains/</a></span></div></li><li id="https://www.pharmaceutical-technology.com/projects/genzyme-ireland/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmaceutical-technology.com/projects/genzyme-ireland/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmaceutical-technology.com/projects/genzyme-ireland/</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/732485/000115752310002162/a6257774-ex991.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/732485/000115752310002162/a6257774-ex991.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/732485/000115752310002162/a6257774-ex991.htm</a></span></div></li><li id="https://www.sanofi.us/en/our-company" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.us/en/our-company" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.us/en/our-company</a></span></div></li><li id="https://www.highperformr.ai/company/sanofigenzyme" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.highperformr.ai/company/sanofigenzyme" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.highperformr.ai/company/sanofigenzyme</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/1121404/000119312511115014/dex993.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/1121404/000119312511115014/dex993.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/1121404/000119312511115014/dex993.htm</a></span></div></li><li id="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491</a></span></div></li><li id="https://products.sanofi.us/cerezyme/cerezyme.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://products.sanofi.us/cerezyme/cerezyme.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://products.sanofi.us/cerezyme/cerezyme.html</a></span></div></li><li id="https://go.drugbank.com/drugs/DB00103" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB00103" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB00103</a></span></div></li><li id="https://www.news.sanofi.us/2021-03-12-Long-term-data-on-Fabrazyme-R-agalsidase-beta-for-people-with-Fabry-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news.sanofi.us/2021-03-12-Long-term-data-on-Fabrazyme-R-agalsidase-beta-for-people-with-Fabry-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news.sanofi.us/2021-03-12-Long-term-data-on-Fabrazyme-R-agalsidase-beta-for-people-with-Fabry-disease</a></span></div></li><li id="https://www.drugs.com/history/myozyme.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/history/myozyme.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/history/myozyme.html</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/</a></span></div></li><li id="https://www.genzymebiosurgery.com/our-products/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.genzymebiosurgery.com/our-products/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.genzymebiosurgery.com/our-products/</a></span></div></li><li id="https://products.sanofi.us/synviscone/synviscone.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://products.sanofi.us/synviscone/synviscone.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://products.sanofi.us/synviscone/synviscone.html</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/732485/000104746904012081/a2133569zex-99_1.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/732485/000104746904012081/a2133569zex-99_1.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/732485/000104746904012081/a2133569zex-99_1.htm</a></span></div></li><li id="https://www.bioworld.com/articles/452280" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bioworld.com/articles/452280" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bioworld.com/articles/452280</a></span></div></li><li id="https://www.medscape.com/viewarticle/712448" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medscape.com/viewarticle/712448" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medscape.com/viewarticle/712448</a></span></div></li><li id="https://www.sanofi.com/en/our-science/our-pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/en/our-science/our-pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/en/our-science/our-pipeline</a></span></div></li><li id="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development</a></span></div></li><li id="https://www.rarediseases.sanofimedical.com/Pipeline" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.rarediseases.sanofimedical.com/Pipeline" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.rarediseases.sanofimedical.com/Pipeline</a></span></div></li><li id="https://www.bizjournals.com/boston/news/2022/12/15/boston-area-biotech-pioneer-on-the-orphan-drug-re.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bizjournals.com/boston/news/2022/12/15/boston-area-biotech-pioneer-on-the-orphan-drug-re.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bizjournals.com/boston/news/2022/12/15/boston-area-biotech-pioneer-on-the-orphan-drug-re.html</a></span></div></li><li id="https://www.nature.com/articles/nbt1010-1018" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nbt1010-1018" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nbt1010-1018</a></span></div></li><li id="https://www.ddw-online.com/biotechnology-based-orphan-drugs-achievements-and-challenges-1584-200310/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ddw-online.com/biotechnology-based-orphan-drugs-achievements-and-challenges-1584-200310/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ddw-online.com/biotechnology-based-orphan-drugs-achievements-and-challenges-1584-200310/</a></span></div></li><li id="https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/alglucerase-injection-ceredaser-gaucher-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/alglucerase-injection-ceredaser-gaucher-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/alglucerase-injection-ceredaser-gaucher-disease</a></span></div></li><li id="https://www.hbs.edu/faculty/Pages/item.aspx?num=28922" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hbs.edu/faculty/Pages/item.aspx?num=28922" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hbs.edu/faculty/Pages/item.aspx?num=28922</a></span></div></li><li id="https://www.prnewswire.com/news-releases/sanofi-sales-growth-of-69-thanks-to-genzyme-acquisition-and-performance-of-growth-platforms-126311908.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/sanofi-sales-growth-of-69-thanks-to-genzyme-acquisition-and-performance-of-growth-platforms-126311908.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/sanofi-sales-growth-of-69-thanks-to-genzyme-acquisition-and-performance-of-growth-platforms-126311908.html</a></span></div></li><li id="https://www.cerezyme.com/considering-cerezyme/clinical-studies" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cerezyme.com/considering-cerezyme/clinical-studies" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cerezyme.com/considering-cerezyme/clinical-studies</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3564370/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3564370/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3564370/</a></span></div></li><li id="https://www.europeanpharmaceuticalreview.com/article/233622/enzyme-replacement-therapy-improving-outcomes-in-rare-disease/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.europeanpharmaceuticalreview.com/article/233622/enzyme-replacement-therapy-improving-outcomes-in-rare-disease/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.europeanpharmaceuticalreview.com/article/233622/enzyme-replacement-therapy-improving-outcomes-in-rare-disease/</a></span></div></li><li id="https://www.marketwatch.com/story/genzyme-to-buy-novazyme-for-up-to-225-million" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.marketwatch.com/story/genzyme-to-buy-novazyme-for-up-to-225-million" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.marketwatch.com/story/genzyme-to-buy-novazyme-for-up-to-225-million</a></span></div></li><li id="https://www.ftc.gov/news-events/news/press-releases/2004/01/ftc-closes-its-investigation-genzyme-corporations-2001-acquisition-novazyme-pharmaceuticals-inc" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ftc.gov/news-events/news/press-releases/2004/01/ftc-closes-its-investigation-genzyme-corporations-2001-acquisition-novazyme-pharmaceuticals-inc" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ftc.gov/news-events/news/press-releases/2004/01/ftc-closes-its-investigation-genzyme-corporations-2001-acquisition-novazyme-pharmaceuticals-inc</a></span></div></li><li id="https://ir.ionis.com/news-releases/news-release-details/genzyme-and-isis-announce-strategic-alliance-including-exclusive" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.ionis.com/news-releases/news-release-details/genzyme-and-isis-announce-strategic-alliance-including-exclusive" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.ionis.com/news-releases/news-release-details/genzyme-and-isis-announce-strategic-alliance-including-exclusive</a></span></div></li><li id="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-genzyme-announce-restructuring" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-genzyme-announce-restructuring" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-genzyme-announce-restructuring</a></span></div></li><li id="https://www.biopharminternational.com/view/genzyme-detects-virus-contamination-bioreactor-halts-production" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biopharminternational.com/view/genzyme-detects-virus-contamination-bioreactor-halts-production" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biopharminternational.com/view/genzyme-detects-virus-contamination-bioreactor-halts-production</a></span></div></li><li id="https://www.nytimes.com/2010/04/16/business/16genzyme.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nytimes.com/2010/04/16/business/16genzyme.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nytimes.com/2010/04/16/business/16genzyme.html</a></span></div></li><li id="https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009</a></span></div></li><li id="https://www.bloomberg.com/news/articles/2011-09-15/sanofi-s-genzyme-sees-limited-cerezyme-supplies-through-january" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bloomberg.com/news/articles/2011-09-15/sanofi-s-genzyme-sees-limited-cerezyme-supplies-through-january" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bloomberg.com/news/articles/2011-09-15/sanofi-s-genzyme-sees-limited-cerezyme-supplies-through-january</a></span></div></li><li id="https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients</a></span></div></li><li id="https://www.massdevice.com/whistleblower-lawsuit-costs-genzyme-22m/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.massdevice.com/whistleblower-lawsuit-costs-genzyme-22m/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.massdevice.com/whistleblower-lawsuit-costs-genzyme-22m/</a></span></div></li><li id="https://www.justice.gov/archives/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/archives/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/archives/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm</a></span></div></li><li id="https://www.gibsondunn.com/wp-content/uploads/documents/publications/Genzyme-DPA-and-Attachments.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gibsondunn.com/wp-content/uploads/documents/publications/Genzyme-DPA-and-Attachments.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gibsondunn.com/wp-content/uploads/documents/publications/Genzyme-DPA-and-Attachments.pdf</a></span></div></li><li id="https://nj.gov/oag/newsreleases14/pr20140312a.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nj.gov/oag/newsreleases14/pr20140312a.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nj.gov/oag/newsreleases14/pr20140312a.html</a></span></div></li><li id="https://ca.finance.yahoo.com/news/sanofis-genzyme-pays-32-59-million-criminal-seprafilm-000515813--finance.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ca.finance.yahoo.com/news/sanofis-genzyme-pays-32-59-million-criminal-seprafilm-000515813--finance.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ca.finance.yahoo.com/news/sanofis-genzyme-pays-32-59-million-criminal-seprafilm-000515813--finance.html</a></span></div></li><li id="https://www.justice.gov/d9/press-releases/attachments/2015/09/03/genzyme_dpa_attachment_b.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/d9/press-releases/attachments/2015/09/03/genzyme_dpa_attachment_b.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/d9/press-releases/attachments/2015/09/03/genzyme_dpa_attachment_b.pdf</a></span></div></li><li id="https://news.bloomberglaw.com/white-collar-and-criminal-law/genzyme-to-pay-325m-for-false-marketing-of-seprafilm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.bloomberglaw.com/white-collar-and-criminal-law/genzyme-to-pay-325m-for-false-marketing-of-seprafilm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.bloomberglaw.com/white-collar-and-criminal-law/genzyme-to-pay-325m-for-false-marketing-of-seprafilm</a></span></div></li><li id="https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020</a></span></div></li><li id="https://www.statnews.com/wp-content/uploads/2024/02/Genzyme-Fourth-Amended-Complaint.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statnews.com/wp-content/uploads/2024/02/Genzyme-Fourth-Amended-Complaint.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statnews.com/wp-content/uploads/2024/02/Genzyme-Fourth-Amended-Complaint.pdf</a></span></div></li><li id="https://patentdocs.org/2011/03/10/fabry-patients-sue-genyzme-for-damages-caused-by-fabrazyme-rationing/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://patentdocs.org/2011/03/10/fabry-patients-sue-genyzme-for-damages-caused-by-fabrazyme-rationing/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://patentdocs.org/2011/03/10/fabry-patients-sue-genyzme-for-damages-caused-by-fabrazyme-rationing/</a></span></div></li><li id="https://www.nature.com/articles/nm.2440.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nm.2440.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nm.2440.pdf</a></span></div></li><li id="https://law.justia.com/cases/federal/appellate-courts/ca1/15-1446/15-1446-2016-05-23.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://law.justia.com/cases/federal/appellate-courts/ca1/15-1446/15-1446-2016-05-23.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://law.justia.com/cases/federal/appellate-courts/ca1/15-1446/15-1446-2016-05-23.html</a></span></div></li><li id="https://www.nytimes.com/2008/03/16/business/16gaucher.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nytimes.com/2008/03/16/business/16gaucher.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nytimes.com/2008/03/16/business/16gaucher.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4289531/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4289531/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4289531/</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=15286" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=15286" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=15286</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf</a></span></div></li><li id="https://www.govinfo.gov/content/pkg/USCOURTS-mad-1_09-cv-11299/pdf/USCOURTS-mad-1_09-cv-11299-0.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.govinfo.gov/content/pkg/USCOURTS-mad-1_09-cv-11299/pdf/USCOURTS-mad-1_09-cv-11299-0.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.govinfo.gov/content/pkg/USCOURTS-mad-1_09-cv-11299/pdf/USCOURTS-mad-1_09-cv-11299-0.pdf</a></span></div></li><li id="https://www.fiercebiotech.com/biotech/genzyme-successfully-meets-first-milestones-of-fda-consent-decree" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercebiotech.com/biotech/genzyme-successfully-meets-first-milestones-of-fda-consent-decree" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercebiotech.com/biotech/genzyme-successfully-meets-first-milestones-of-fda-consent-decree</a></span></div></li><li id="https://www.biospace.com/fda-approves-genzyme-corporation-s-myozyme-r-for-all-patients-with-pompe-disease-drug-to-carry-warning" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/fda-approves-genzyme-corporation-s-myozyme-r-for-all-patients-with-pompe-disease-drug-to-carry-warning" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/fda-approves-genzyme-corporation-s-myozyme-r-for-all-patients-with-pompe-disease-drug-to-carry-warning</a></span></div></li><li id="https://www.fiercepharma.com/pharma/genzyme-announces-european-approval-of-framingham-manufacturing-plant" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/genzyme-announces-european-approval-of-framingham-manufacturing-plant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/genzyme-announces-european-approval-of-framingham-manufacturing-plant</a></span></div></li><li id="https://www.pharmexec.com/view/genzyme-price-success" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmexec.com/view/genzyme-price-success" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmexec.com/view/genzyme-price-success</a></span></div></li><li id="https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html</a></span></div></li><li id="https://www.nature.com/articles/nm0511-522b" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nm0511-522b" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nm0511-522b</a></span></div></li><li id="https://sourceonhealthcare.org/orphan-drug-act-fostering-innovation-or-abuse/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://sourceonhealthcare.org/orphan-drug-act-fostering-innovation-or-abuse/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://sourceonhealthcare.org/orphan-drug-act-fostering-innovation-or-abuse/</a></span></div></li><li id="https://www.catribunal.org.uk/sites/cat/files/Jdg1016Genzy110304.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.catribunal.org.uk/sites/cat/files/Jdg1016Genzy110304.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.catribunal.org.uk/sites/cat/files/Jdg1016Genzy110304.pdf</a></span></div></li><li id="https://www.biospace.com/genzyme-corporation-launches-initiative-to-assist-the-development-of-treatments-for-neglected-diseases" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.biospace.com/genzyme-corporation-launches-initiative-to-assist-the-development-of-treatments-for-neglected-diseases" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.biospace.com/genzyme-corporation-launches-initiative-to-assist-the-development-of-treatments-for-neglected-diseases</a></span></div></li><li id="https://academic.oup.com/shm/article/32/3/609/4663001" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/shm/article/32/3/609/4663001" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/shm/article/32/3/609/4663001</a></span></div></li><li id="https://www.prnewswire.com/news-releases/sanofi-aventis-completes-acquisition-of-genzyme-corporation-119496769.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/sanofi-aventis-completes-acquisition-of-genzyme-corporation-119496769.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/sanofi-aventis-completes-acquisition-of-genzyme-corporation-119496769.html</a></span></div></li><li id="https://www.fiercepharma.com/pharma/sanofi-moves-deeper-into-genzyme-operations" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/sanofi-moves-deeper-into-genzyme-operations" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/sanofi-moves-deeper-into-genzyme-operations</a></span></div></li><li id="https://www.boston.com/uncategorized/noprimarytagmatch/2011/06/14/sanofi-putting-its-stamp-on-genzyme/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.boston.com/uncategorized/noprimarytagmatch/2011/06/14/sanofi-putting-its-stamp-on-genzyme/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.boston.com/uncategorized/noprimarytagmatch/2011/06/14/sanofi-putting-its-stamp-on-genzyme/</a></span></div></li><li id="https://www.news.sanofi.us/press-releases?item=121274" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news.sanofi.us/press-releases?item=121274" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news.sanofi.us/press-releases?item=121274</a></span></div></li><li id="https://www.europeanpharmaceuticalreview.com/news/33346/sanofi-announces-new-global-business-unit-structure/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.europeanpharmaceuticalreview.com/news/33346/sanofi-announces-new-global-business-unit-structure/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.europeanpharmaceuticalreview.com/news/33346/sanofi-announces-new-global-business-unit-structure/</a></span></div></li><li id="https://www.fiercepharma.com/pharma/sanofi-announces-new-global-business-unit-structure-to-drive-future-growth" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercepharma.com/pharma/sanofi-announces-new-global-business-unit-structure-to-drive-future-growth" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercepharma.com/pharma/sanofi-announces-new-global-business-unit-structure-to-drive-future-growth</a></span></div></li><li id="https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/</a></span></div></li><li id="https://www.fiercebiotech.com/biotech/post-merger-genzyme-opens-up-throttle-on-r-d-plans" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fiercebiotech.com/biotech/post-merger-genzyme-opens-up-throttle-on-r-d-plans" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fiercebiotech.com/biotech/post-merger-genzyme-opens-up-throttle-on-r-d-plans</a></span></div></li><li id="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-blood-disorders" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/en/our-science/therapeutic-areas/rare-blood-disorders" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/en/our-science/therapeutic-areas/rare-blood-disorders</a></span></div></li><li id="https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf</a></span></div></li><li id="https://www.pharmalive.com/sanofi-2025-from-the-incurable-to-the-manageable/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pharmalive.com/sanofi-2025-from-the-incurable-to-the-manageable/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pharmalive.com/sanofi-2025-from-the-incurable-to-the-manageable/</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk" id="_R_" async=""></script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Genzyme\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Genzyme\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Genzyme\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T12536,"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"# Genzyme\n\n![Genzyme headquarters](./_assets_/Genzyme_building.jpg)  \nGenzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health.[](https://www.reuters.com/article/2011/02/16/sanofi-genzyme-facts-idUSLDE71F0HY20110216/)[](https://nationalmedals.org/laureate/genzyme-incorporated/) The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations.[](https://www.statnews.com/sponsor/2020/01/30/building-on-a-legacy-of-enzyme-replacement-therapy-to-fuel-rare-disease-treatment/)[](https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html)  \n\nUnder the leadership of subsequent executives including Henri Termeer, Genzyme introduced landmark products such as Ceredase and its successor Cerezyme (imiglucerase) for Gaucher's disease in the early 1990s, marking the first approved enzyme replacement therapy for the condition, and Fabrazyme (agalsidase beta) for Fabry disease.[](https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/)[](https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry) These innovations established a viable commercial model for orphan drugs, leveraging regulatory incentives amid high development costs and limited markets, though treatments commanded premium prices often exceeding $200,000 annually per patient.[](https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html)[](https://now.tufts.edu/2012/04/12/flair-business-medicine)  \n\nGenzyme's growth culminated in its 2011 acquisition by Sanofi-aventis for $74 per share in cash, totaling approximately $20.1 billion, which integrated its rare disease expertise into a global pharmaceutical powerhouse while preserving the Genzyme brand for specialized operations.[](https://www.news.sanofi.us/press-releases?item=118549) The company encountered significant challenges, including a 2009 viral contamination at its Allston manufacturing facility that triggered prolonged shortages of Cerezyme and Fabrazyme, resulting in patient harm allegations and ongoing litigation over rationed dosing strategies.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/)[](https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/)[](https://caselaw.findlaw.com/court/us-1st-circuit/115829215.html)\n\n## History\n\n### Founding and Early Development (1981-1989)\n\nGenzyme Corporation was founded on June 8, 1981, in Boston, Massachusetts, by venture capitalists Sheridan Snyder and George M. Whitesides alongside scientist Henry Blair, who served as the company's scientific founder.[](https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/)[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) The initial office and laboratory were established on the Tufts University campus in Medford, Massachusetts, with Blair leveraging his National Institutes of Health contract to focus on enzyme-based technologies for diagnostics and therapeutics.[](https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/) Supported by venture capital, the company quickly pursued acquisitions to build its biochemical capabilities, including Whatman Biochemicals Ltd. in 1981, which formed the basis of Genzyme Biochemicals, and Koch-Light Laboratories, a British chemical supplier, in 1982.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html)\n\nIn 1983, Henri Termeer joined as chairman and president, becoming CEO in 1985, and redirected the firm's efforts toward developing treatments for rare genetic diseases, notably enzyme replacement therapy for Gaucher's disease using alglucerase derived from human placental tissue.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) Under Termeer, Genzyme emphasized carbohydrate and enzyme technologies, producing early diagnostic reagents such as cholesterol oxidase for cholesterol testing kits.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) This period marked the company's transition from biochemical supply to biotech innovation, with initial clinical trials for Gaucher's therapy commencing around 1983 amid challenges in scaling enzyme production.[](https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/)\n\nBy 1986, Genzyme went public through an initial public offering that raised $28.2 million, enabling expansion including a Japanese subsidiary and a Cambridge, Massachusetts, facility for hyaluronic acid production.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) The firm secured $10 million in partnerships specifically for advancing Ceredase, its Gaucher's treatment candidate.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) In 1988, it opened a pharmaceutical chemical plant in Haverhill, United Kingdomâ€”partially funded by the UK Department of Trade and Industryâ€”and received FDA approval for clindamycin phosphate, an antibiotic product.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) The decade closed with the 1989 acquisition of Integrated Genetics for $31.5 million to bolster genetic engineering capabilities, additional financing of $39.1 million via stock offerings and $36.8 million for hyaluronic acid drug development, and the formation of a diagnostics division, culminating in $34.1 million in annual revenues.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html)\n\n### Expansion and Key Product Launches (1990-1999)\n\n![Genzyme plant in Allston, Massachusetts](./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg)\nThe successful launch of Ceredase (alglucerase injection) in 1991 propelled Genzyme's expansion, marking the company's first major commercial product for treating type 1 Gaucher disease through enzyme replacement therapy derived from human placental glucocerebrosidase. The U.S. Food and Drug Administration (FDA) approved Ceredase on April 5, 1991, following its availability outside the United States starting in 1990, which addressed a rare lysosomal storage disorder affecting approximately 20,000 patients worldwide at the time. This breakthrough drove significant revenue growth, with sales rising from $54.8 million in 1990 to $121.7 million in 1991, more than doubling the company's financial performance and enabling further investment in biotechnology infrastructure.[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=5585)[](https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf)[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html)\n\nTo address supply constraints inherent in placental sourcing, Genzyme developed Cerezyme (imiglucerase), a recombinant human glucocerebrosidase produced via mammalian cell culture, which received FDA approval on May 23, 1994, as a more scalable alternative for Gaucher disease treatment. This product launch coincided with the opening of the Allston Landing manufacturing facility in 1996, constructed beginning in the early 1990s to support recombinant protein production, including Cerezyme, and representing a key step in Genzyme's shift toward sustainable biomanufacturing capabilities. Revenues continued to expand, reaching $265.7 million in 1993 and $310.7 million in 1994, reflecting 17% year-over-year growth driven primarily by enzyme therapies.[](https://purplebooksearch.fda.gov/productdetails?query=020367)[](https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant)[](https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/)[](https://www.bioworld.com/articles/396653-genzyme-reports-profits-of-14m-for-1994)\n\nGenzyme pursued diversification through strategic acquisitions and additional product launches in the mid-to-late 1990s, including the 1992 purchases of Integrated Genetics for genetic engineering expertise, Gencore International for distribution networks, and Medix Biotech for diagnostic reagents, which broadened its therapeutic and operational scope. In 1996, the company introduced Seprafilm, a bioresorbable adhesion barrier approved by the FDA on March 25, 1996, designed to reduce postoperative adhesions in abdominal and pelvic surgeries. The following year, Carticel (autologous cultured chondrocytes) gained FDA approval in August 1997 as the first cell-based therapy for repairing knee cartilage defects, entering a nascent field of tissue engineering. These initiatives, alongside a 1996 collaboration with Imperial Cancer Research Technology Ltd. to bolster oncology research, underscored Genzyme's evolution from a niche enzyme-focused firm to a multifaceted biotechnology leader by decade's end.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html)[](https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/)[](https://www.nature.com/articles/nbt0596-572a.pdf)[](https://www.bioworld.com/articles/364972-fda-approves-genzyme-s-carticel-for-cartilage-repair)\n\n### Diversification, Growth, and Pre-Acquisition Challenges (2000-2010)\n\nIn the early 2000s, Genzyme diversified its portfolio beyond lysosomal storage disorders by acquiring companies to enter biosurgery, transplant immunology, and oncology. In 2000, it acquired Biomatrix, Inc., adding Synvisc, a viscosupplement for osteoarthritis treatment, which formed the basis of its Genzyme Biosurgery division.[](https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/) In 2001, Genzyme purchased Novazyme Pharmaceuticals for $457 million, gaining enzyme replacement therapy technology for Pompe disease, leading to the development of Myozyme (alglucosidase alfa), approved by the FDA in 2006.[](https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/) Further acquisitions included SangStat Medical Corporation in 2003 for Thymoglobulin, an immunosuppressant for organ transplant rejection, and AnorMED in 2006 for plerixafor (Mozobil), a stem cell mobilizer for multiple myeloma and lymphoma patients.[](https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/)[](https://biopharmguy.com/links/company-by-name-acquisitions.php) These moves created five focused business unitsâ€”therapeutics, biosurgery, transplant, oncology, and geneticsâ€”reducing reliance on flagship products like Cerezyme (imiglucerase) for Gaucher disease.[](https://www.sec.gov/Archives/edgar/vprr/0505/05050784.pdf)\n\nRevenue growth accelerated through product launches, international expansion, and diversified sales. From 2001 to 2006, annual sales grew at a compound annual rate of approximately 27 percent, reaching $3.19 billion in 2006, driven by increased demand for rare disease therapies and new approvals like Renagel (sevelamer) for hyperphosphatemia in chronic kidney disease.[](https://www.sec.gov/Archives/edgar/data/732485/000110465907001467/a07-1497_1ex99d1.htm) By 2010, total revenue approached $4.4â€“4.5 billion, with non-GAAP earnings per share projected at $3.85â€“$3.95, reflecting contributions from multiple segments including oncology (e.g., Campath for chronic lymphocytic leukemia, acquired via ILEX Oncology in 2004) and global manufacturing investments.[](https://www.fiercebiotech.com/biotech/genzyme-reports-financial-results-for-second-quarter-of-2010) Genzyme also unified its capital structure in 2003 by eliminating tracking stocks, streamlining operations and enabling focused R\u0026D investments exceeding $700 million annually by the late 2000s.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm)\n\n![Genzyme Allston plant](./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg)\n\nDespite growth, Genzyme encountered severe pre-acquisition challenges, particularly manufacturing disruptions in 2009â€“2010 that affected supply of critical drugs. In June 2009, a viral contamination (vesivirus 211) in Chinese hamster ovary cells at the Allston, Massachusetts facility halted production of Cerezyme and Fabrazyme (agalsidase beta for Fabry disease), leading to global shortages; by July, Genzyme could meet only 50 percent of Cerezyme demand.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/)[](https://www.nytimes.com/2009/06/17/business/17drug.html) The FDA issued multiple warning letters, citing inadequate quality controls and particulate contamination in products, prompting a consent decree in May 2010 requiring facility upgrades and independent oversight, with potential fines up to $175 million.[](https://www.fiercepharma.com/pharma/genzyme-corp-signs-consent-decree-to-correct-violations-at-allston-mass-manufacturing-plant)[](https://www.soci.org/chemistry-and-industry/cni-data/2010/9/genzyme-faces-175m-fda-fines) These issues caused Cerezyme sales to drop 30 percent in 2009 and overall revenue growth to stall, exacerbating investor pressure and positioning the company for acquisition amid unresolved supply constraints.[](https://www.cram.com/essay/Analysis-Of-Enzyme-Corporation/PKHMCUAZ7BQQ)[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/)\n\n### Acquisition by Sanofi (2011)\n\nIn February 2010, Sanofi-aventis submitted a non-binding proposal to acquire Genzyme in an all-cash transaction valued at approximately $18.5 billion, which Genzyme rejected as undervaluing the company amid ongoing manufacturing challenges and product pipeline potential.[](https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm) Negotiations continued, culminating in an agreement announced on February 16, 2011, for Sanofi-aventis to acquire Genzyme for $74.00 per share in cash, representing an equity value of about $20.1 billion, plus one contingent value right (CVR) per share potentially worth up to additional payments tied to milestones such as resolution of manufacturing issues for Cerezyme and Fabrazyme and regulatory approval of Lemtrada (alemtuzumab).[](https://www.news.sanofi.us/press-releases?item=118549)[](https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/) The deal addressed Genzyme's vulnerabilities, including a U.S. FDA consent decree from 2009 over production contamination and supply shortages for critical rare disease therapies, which had eroded investor confidence and share value despite Genzyme's leadership in enzyme replacement therapies.[](https://www.fiercepharma.com/manufacturing/sanofi-genzyme-deal-makes-consent-decree-a-mere-detail)\n\nThe acquisition received antitrust clearance from the European Commission on January 12, 2011, under Merger Regulation case COMP/M.5999, determining no significant competition concerns in the rare disease and biologics markets, and from the U.S. Federal Trade Commission prior to the announcement.[](https://ec.europa.eu/competition/mergers/cases/decisions/m5999_20110112_20310_2550120_EN.pdf)[](https://www.news.sanofi.us/press-releases?item=118549) Sanofi-aventis launched a tender offer for Genzyme shares, which expired on April 1, 2011, after sufficient acceptance to proceed, followed by a short-form merger on April 8, 2011, delisting Genzyme from NASDAQ without further shareholder vote and integrating it as a subsidiary focused on rare diseases.[](https://www.fiercepharma.com/pharma/sanofi-aventis-completes-acquisition-of-genzyme-corporation)[](https://www.europeanpharmaceuticalreview.com/news/6539/sanofi-aventis-completes-acquisition-of-genzyme-corporation/)\n\nStrategically, the acquisition bolstered Sanofi's position in high-margin rare disease treatments, diversifying from its traditional pharmaceutical portfolio into biologics and orphan drugs, where Genzyme generated over 80% of its revenue from therapies like Cerezyme for Gaucher disease.[](https://www.npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion) Sanofi committed to investing in resolving Genzyme's manufacturing constraints, including upgrades at facilities in Allston, Massachusetts, to restore full production capacity and mitigate supply risks that had previously led to patient rationing.[](https://www.prnewswire.com/news-releases/sanofi-aventis-to-acquire-genzyme-for-7400-in-cash-per-share-plus-contingent-value-right-116291094.html) Post-acquisition, Genzyme operated semi-autonomously under Sanofi Genzyme, preserving its specialized R\u0026D focus while leveraging Sanofi's global infrastructure for commercialization.[](https://www.fiercebiotech.com/biotech/sanofi-aventis-to-acquire-genzyme-for-74-00-cash-per-share-plus-contingent-value-right)\n\n## Business Operations\n\n### Organizational Structure and Divisions\n\nGenzyme Corporation maintained a divisional organizational structure designed to support specialized biotechnology development and commercialization in niche therapeutic areas, with each division operating semi-autonomously to address distinct market needs and regulatory environments. Prior to its acquisition by Sanofi in 2011, the company reported through four primary business segments: Therapeutics, Renal, Transplant, and Biosurgery.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm) The Therapeutics division concentrated on enzyme replacement and substrate reduction therapies for rare genetic disorders, including products such as Cerezyme for Gaucher disease (generating $733.8 million in revenue in 2003, representing 47% of total product revenue) and Fabrazyme for Fabry disease.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm) The Renal division focused on treatments for chronic kidney disease, led by Renagel, a phosphate binder that accounted for $281.7 million in revenue (18% of product revenue) in 2003.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm)\n\nThe Transplant division developed immunosuppressive agents to prevent organ rejection and treat autoimmune conditions, with flagship products including Thymoglobulin and Lymphoglobuline.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm) Biosurgery targeted surgical and orthopedic applications through biotherapeutics and biomaterials, such as Synvisc for viscosupplementation in osteoarthritis and Seprafilm for reducing postoperative adhesions.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm) Additionally, Genzyme operated a Diagnostics segment providing genetic testing services and diagnostic products, though it contributed a smaller share of overall revenue. This structure evolved from earlier configurations, including the discontinuation of standalone Genzyme General and Genzyme Molecular Oncology divisions by mid-2003, consolidating operations under unified financial reporting while retaining therapeutic focus.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm)\n\nFollowing Sanofi's $20.1 billion acquisition in June 2011, Genzyme's rare disease operationsâ€”primarily the legacy Therapeutics segmentâ€”were preserved as a standalone division under the Sanofi Genzyme brand to maintain specialized expertise and brand continuity, with dedicated leadership and resources integrated into Sanofi's broader portfolio.[](https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm) Other segments, such as Renal-Endocrinology, Hematology-Oncology, and Biosurgery, were aligned with complementary Sanofi units to enhance synergies in distribution and R\u0026D.[](https://www.news.sanofi.us/press-releases?item=118549) This hybrid model allowed Genzyme's divisions to benefit from Sanofi's global infrastructure while minimizing disruption to high-margin orphan drug operations, though full integration led to the phase-out of the Genzyme name for non-rare disease activities by 2022.[](https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/)\n\n### Manufacturing and Supply Chain\n\n![Genzyme plant, Allston, Massachusetts](./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg)\nGenzyme's manufacturing operations centered on biologics production for rare disease therapies, with primary facilities in Massachusetts. The company's flagship plant in Allston, Boston, served as a key site for producing enzyme replacement therapies like Cerezyme and Fabrazyme, undergoing expansion starting in September 2007 to meet growing demand.[](https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/) [](https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant) In 2013, Genzyme invested $80 million to expand capacity at its Framingham, Massachusetts facility specifically for Fabrazyme production.[](https://www.fiercepharma.com/manufacturing/genzyme-to-invest-80-million-framingham-mass-site-to-expand-manufacturing-capacity) Following the 2011 acquisition by Sanofi, Genzyme's operations integrated into Sanofi's global network, which included 17 manufacturing sites worldwide as of that period.[](https://www.sanofi.com/en/our-science/manufacturing-and-supply)\n\nA significant disruption occurred in 2009 when viral contamination at the Allston facility halted production of Cerezyme and Fabrazyme. On March 2, 2009, the FDA issued a warning letter citing manufacturing deficiencies at the site, followed by detection of Vesivirus 2117 contamination on June 16, 2009, prompting a shutdown for cleaning and remediation.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/) [](https://www.nytimes.com/2009/06/17/business/17drug.html) This led to global shortages of these critical drugs, with analysts estimating revenue losses of $100â€“300 million in 2009 alone, and prolonged supply constraints for Fabrazyme into 2012.[](https://www.nature.com/articles/nbt0809-681a) In May 2010, Genzyme agreed to surrender $175 million to resolve FDA charges of inadequate quality systems during inspections from September 2009 to November 2009.[](https://www.biospace.com/genzyme-corporation-surrenders-175-million-for-violations-at-mass-facility) The Allston plant was later leased to National Resilience in 2021.[](https://news.harvard.edu/gazette/story/2021/03/national-resilience-takes-over-genzyme-sanofi-building-in-allston/)\n\nGenzyme's supply chain relied heavily on these specialized facilities, exposing vulnerabilities to single-site failures, as evidenced by the 2009 crisis and subsequent litigation over Fabrazyme shortages.[](https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/) To mitigate risks, the company pursued diversified production strategies across multiple sites.[](https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118115800.ch4) Post-acquisition, Sanofi enhanced capabilities with continuous biologics manufacturing at Framingham, one of the first digitally enabled facilities of its kind.[](https://www.sanofi.com/en/our-science/manufacturing-and-supply) However, challenges persisted; in January 2025, the FDA issued a warning letter to Sanofi for bioreactor irregularities at the Framingham Genzyme plant, though the company stated the supply chain remained unaffected.[](https://www.dermatologyadvisor.com/news/fda-warns-sanofi-of-manufacturing-irregularities-at-key-facility/)[](https://www.pharmamanufacturing.com/industry-news/news/55262524/sanofi-gets-fda-warning-letter-for-genzyme-plant-supply-chain-remains-unaffected) Sanofi Genzyme continues to focus on resilience in its complex global supply chain for rare disease products.[](https://www.aboutresilience.com/resilience-strategies-for-complex-supply-chains/)\n\n### Global Reach and Workforce\n\nGenzyme began its international expansion in the mid-1980s to support growing demand for its diagnostic and therapeutic products. In 1986, the company established a subsidiary in Japan, financed through local sales.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) This was followed in 1988 by the opening of a pharmaceutical chemical manufacturing plant in Haverhill, United Kingdom.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html) By 1991, Genzyme had formed Genzyme B.V., a European subsidiary in Naarden, Netherlands, with ongoing operations in the Netherlands, Japan, and England.[](https://www.company-histories.com/Genzyme-Corporation-Company-History.html)\n\nThe company further developed its global manufacturing capabilities, including a major campus in Waterford, Ireland, operational by 2003 for solid-dose production of Renagel tablets and later expanded for biologics fill-finish processes.[](https://www.pharmaceutical-technology.com/projects/genzyme-ireland/) This site employed 370 workers by the end of 2006 and grew to over 600 by 2008 after â‚¬150 million in additional investment, contributing to cumulative spending exceeding â‚¬410 million by 2010.[](https://www.pharmaceutical-technology.com/projects/genzyme-ireland/) By the late 2000s, Genzyme maintained over 70 locations across 30 countries to facilitate product development, manufacturing, and distribution.[](https://www.pharmaceutical-technology.com/projects/genzyme-ireland/)\n\nGenzyme's workforce expanded alongside its footprint, reaching more than 12,000 employees worldwide by 2010, supporting operations from research to patient delivery.[](https://www.sec.gov/Archives/edgar/data/732485/000115752310002162/a6257774-ex991.htm) After Sanofi's 2011 acquisition, Genzyme's activities integrated into the parent company's network, which operates in over 100 countries and leverages specialized sites for rare disease therapies, including facilities in Framingham, Massachusetts; Waterford, Ireland; and Haverhill, United Kingdom.[](https://www.sanofi.us/en/our-company)[](https://www.highperformr.ai/company/sanofigenzyme) This structure sustains Genzyme's capacity to reach patients in nearly 100 countries.[](https://www.sec.gov/Archives/edgar/data/1121404/000119312511115014/dex993.htm)\n\n## Products and Therapeutic Focus\n\n### Rare Disease Therapies\n\nGenzyme specialized in enzyme replacement therapies (ERTs) for lysosomal storage disorders, a group of rare inherited metabolic diseases resulting from genetic deficiencies in enzymes that degrade cellular waste, leading to substrate accumulation and organ damage. These therapies, administered intravenously, supply functional recombinant enzymes to mitigate symptoms such as organomegaly, skeletal abnormalities, and neurological impairment. By targeting orphan indications with small patient populations, Genzyme leveraged regulatory incentives like the U.S. Orphan Drug Act to develop products that addressed unmet needs in diseases affecting fewer than 200,000 Americans per condition.[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases)\n\nThe company's pioneering ERT for Gaucher disease, Cerezyme (imiglucerase), was approved by the FDA on May 23, 1994, as a long-term treatment for type 1 (non-neuronopathic) Gaucher disease. Cerezyme, a recombinant analog of Î²-glucocerebrosidase produced in Chinese hamster ovary cells, catalyzes the hydrolysis of glucocerebroside accumulated in macrophages, reducing liver and spleen volume, improving anemia, and enhancing bone health in clinical trials involving over 1,000 patients. This followed the 1991 approval of Ceredase (alglucerase), derived from purified human placental glucocerebrosidase, which treated approximately 4,000 patients before supply limitations prompted the shift to recombinant production.[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491)[](https://products.sanofi.us/cerezyme/cerezyme.html)[](https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/)\n\nFabrazyme (agalsidase beta), approved by the FDA on April 24, 2003, provides ERT for Fabry disease, an X-linked disorder caused by Î±-galactosidase A deficiency leading to globotriaosylceramide (GL-3) buildup in vascular endothelium and other tissues. The recombinant human enzyme, dosed at 1 mg/kg biweekly, clears GL-3 inclusions from kidney interstitial capillaries, as demonstrated in phase 3 trials showing histologic improvements and reduced pain in 58 adult males. Long-term data from open-label extensions confirm sustained GL-3 clearance and stabilization of renal function in patients treated for up to 10 years.[](https://go.drugbank.com/drugs/DB00103)[](https://www.news.sanofi.us/2021-03-12-Long-term-data-on-Fabrazyme-R-agalsidase-beta-for-people-with-Fabry-disease)\n\nFor Pompe disease (glycogen storage disease type II), Genzyme's Myozyme (alglucosidase alfa) received FDA approval on April 28, 2006, initially for infantile-onset forms characterized by rapid cardiomegaly and hypotonia due to acid Î±-glucosidase (GAA) deficiency. The recombinant human GAA, produced in Chinese hamster ovary cells, promotes glycogen breakdown in lysosomes, improving ventilator-free survival and cardiac function in pivotal trials of 21 infants, where 72% survived beyond 18 months compared to historical controls. Manufacturing scale-up led to Lumizyme approval in 2010 for late-onset Pompe, expanding access without age restrictions based on bioequivalence data and registry outcomes.[](https://www.drugs.com/history/myozyme.html)[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597)\n\nGenzyme also marketed Aldurazyme (laronidase) for mucopolysaccharidosis type I (MPS I), co-developed with BioMarin and approved by the FDA in March 2003 for Hurler and Hurler-Scheie syndromes. This ERT delivers recombinant Î±-L-iduronidase to degrade accumulated glycosaminoglycans, reducing urinary excretion by 60-70% and improving forced vital capacity in clinical studies of 45 patients.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/)\n\n| Product       | Indication                  | FDA Approval Date | Key Mechanism                          |\n|---------------|-----------------------------|-------------------|----------------------------------------|\n| Cerezyme     | Type 1 Gaucher disease     | May 23, 1994     | Recombinant Î²-glucocerebrosidase hydrolyzes glucocerebroside[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491) |\n| Fabrazyme    | Fabry disease              | April 24, 2003   | Recombinant Î±-galactosidase A clears GL-3 deposits[](https://go.drugbank.com/drugs/DB00103) |\n| Myozyme/Lumizyme | Pompe disease          | April 28, 2006   | Recombinant acid Î±-glucosidase degrades lysosomal glycogen[](https://www.drugs.com/history/myozyme.html) |\n| Aldurazyme   | MPS I (Hurler/Hurler-Scheie) | March 2003      | Recombinant Î±-L-iduronidase breaks down glycosaminoglycans[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/)\n\n### Other Biotech Products\n\nGenzyme developed a range of biotechnology products targeting conditions with higher prevalence than rare genetic disorders, including osteoarthritis, cartilage defects, and thyroid cancer monitoring, through its biosurgery and diagnostics divisions. These products diversified the company's portfolio beyond enzyme replacement therapies, leveraging recombinant proteins, cell-based therapies, and biopolymers derived from natural sources.[](https://www.genzymebiosurgery.com/our-products/)\n\nSynvisc (hylan G-F 20), a cross-linked hyaluronan viscosupplement derived from rooster combs, was approved by the U.S. Food and Drug Administration (FDA) on August 4, 1997, for intra-articular injection to relieve pain in patients with osteoarthritis of the knee who had not responded to conservative non-pharmacological therapy or simple analgesics. The product chemically modifies hyaluronic acid to provide extended joint lubrication and shock absorption, mimicking natural synovial fluid, with a single-dose variant, Synvisc-One, later introduced for convenience. Clinical trials demonstrated statistically significant pain reduction lasting up to six months post-injection compared to placebo.[](https://products.sanofi.us/synviscone/synviscone.html)[](https://www.genzymebiosurgery.com/our-products/)\n\nRenagel (sevelamer hydrochloride), a non-calcium, non-aluminum phosphate-binding polymer, received FDA approval on October 7, 2000, for controlling serum phosphorus levels in chronic kidney disease patients on hemodialysis, addressing hyperphosphatemia to prevent complications like vascular calcification. Unlike traditional binders, it avoids metal ions, reducing risks of aluminum toxicity or hypercalcemia; phase III trials showed equivalent phosphorus control to calcium-based agents with lower calcium-phosphate product levels. The product contributed substantially to revenue, generating $515 million in 2006 amid growing dialysis populations.[](https://www.sec.gov/Archives/edgar/data/732485/000104746904012081/a2133569zex-99_1.htm)[](https://www.bioworld.com/articles/452280)\n\nCarticel (autologous cultured chondrocytes), the first FDA-approved cell therapy for orthopedic use on August 16, 1997, treated symptomatic full-thickness chondral defects of the knee in patients aged 18-55 via periosteal grafting and implantation of expanded autologous cartilage cells to promote tissue regeneration. The process involved harvesting chondrocytes from the patient, culturing them ex vivo, and reimplanting, with long-term studies indicating improved defect filling and function over microfracture alone. This represented an early advance in regenerative medicine for non-rare joint conditions.[](https://www.genzymebiosurgery.com/our-products/)\n\nThyrogen (thyrotropin alfa), a recombinant human thyroid-stimulating hormone produced in Chinese hamster ovary cells, was approved by the FDA on December 23, 1998, as an adjunct for serum thyroglobulin testing and radioiodine ablation in thyroid cancer patients to detect recurrence without inducing hypothyroidism. It enables TSH elevation without thyroid hormone withdrawal, shortening diagnostic preparation time from 4-6 weeks to 1-2 days; pivotal trials confirmed comparable sensitivity to withdrawal methods for thyroglobulin measurement. Annual U.S. sales reached approximately $100 million by the mid-2000s.[](https://www.medscape.com/viewarticle/712448)\n\n### Research and Development Pipeline\n\nSanofi's integration of Genzyme has sustained and expanded research into lysosomal storage disorders (LSDs) and other rare diseases, with a pipeline emphasizing enzyme replacement therapies, substrate reduction approaches, and gene-based interventions as of September 2025.[](https://www.sanofi.com/en/our-science/our-pipeline) This builds on Genzyme's historical leadership in LSD treatments, such as Cerezyme for Gaucher disease, by advancing next-generation modalities to address unmet needs like neurological manifestations and earlier disease intervention.[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development) The rare diseases segment includes approximately 10-15 clinical-stage projects, with several in phase 3 targeting LSDs.[](https://www.sanofi.com/en/our-science/our-pipeline)\n\n| Project/Agent | Target Disease | Phase | Modality/Key Details |\n|---------------|----------------|-------|----------------------|\n| Venglustat | Fabry disease; Gaucher disease type 3 | Phase 3 | Oral glucosylceramide synthase (GCS) inhibitor for substrate reduction; ongoing trials (e.g., PERIDOT, CARAT) evaluate long-term efficacy in renal and neurological symptoms.[](https://www.rarediseases.sanofimedical.com/Pipeline)[](https://www.sanofi.com/en/our-science/our-pipeline) |\n| Nexviazyme (avalglucosidase alfa) | Infantile-onset Pompe disease | Phase 3 (extensions) | Next-generation enzyme replacement therapy; approved for late-onset but investigational expansions for infantile forms focus on improved uptake and sustained glycogen reduction.[](https://www.rarediseases.sanofimedical.com/Pipeline)[](https://www.sanofi.com/en/our-science/our-pipeline) |\n| Cerezyme (imiglucerase) | Gaucher disease type 3 | Investigational (post-approval) | Enzyme replacement therapy; approved for type 1 since 1994, current evaluations target type 3 for neurological involvement in U.S. patients.[](https://www.rarediseases.sanofimedical.com/Pipeline)[](https://www.sanofi.com/en/our-science/our-pipeline) |\n| Efdoralprin alfa | Alpha-1 antitrypsin deficiency (AATD) | Phase 1-3 | AAT fusion protein to enhance lung protection; addresses emphysema in this genetic disorder.[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development)[](https://www.sanofi.com/en/our-science/our-pipeline) |\n\nBeyond LSDs, the pipeline incorporates Genzyme-aligned innovations in rare blood and neuromuscular disorders, such as rilzabrutinib (phase 3 for focal segmental glomerulosclerosis/minimal change disease) and gene editing for sickle cell disease, leveraging technologies like AAV-mediated siRNA and BTK inhibitors.[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development) These efforts prioritize small patient populations through patient registries, AI-driven insights, and collaborations, with recent data from 2025 presentations underscoring potential disease-modifying effects in hemophilia and immune thrombocytopenia.[](https://www.sanofi.com/en/our-science/our-pipeline) Sanofi reported three rare diseases-related regulatory milestones in Q2 2025, reflecting pipeline momentum despite challenges in earlier-stage attrition.\n\n## Innovations and Achievements\n\n### Pioneering Orphan Drug Development\n\nGenzyme Corporation pioneered the commercial development of orphan drugs by targeting rare genetic disorders, particularly lysosomal storage diseases, in an era when such markets were overlooked by larger pharmaceutical firms due to limited patient numbers and high development costs. Founded in 1981 and led by CEO Henri Termeer from 1985, the company capitalized on the U.S. Orphan Drug Act of 1983, which granted seven years of market exclusivity, tax credits, and regulatory incentives to offset the economic risks of treating conditions affecting fewer than 200,000 Americans. This approach demonstrated that biologics for ultra-rare diseases could achieve profitability through premium pricing justified by the absence of alternatives and the complexity of production, thereby establishing a viable business model for the sector.[](https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry)[](https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf)[](https://www.bizjournals.com/boston/news/2022/12/15/boston-area-biotech-pioneer-on-the-orphan-drug-re.html)\n\nA landmark achievement was the 1991 FDA approval of Ceredase (alglucerase), Genzyme's first orphan drug and the initial enzyme replacement therapy (ERT) for type 1 Gaucher disease, a disorder caused by glucocerebrosidase deficiency leading to organ enlargement and bone damage in roughly 6,000 U.S. patients. Harvested from human placental tissue, Ceredase required purification from up to 20,000 placentas per year to meet demand, highlighting the logistical innovations Genzyme implemented to scale supply for small cohorts. The drug's exclusivity under the Orphan Drug Act enabled recoupment of development expenses, with sales reaching $100 million annually by the mid-1990s despite the niche indication.[](https://www.nature.com/articles/nbt1010-1018)[](https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/)[](https://www.ddw-online.com/biotechnology-based-orphan-drugs-achievements-and-challenges-1584-200310/)\n\nGenzyme advanced this model in 1994 with Cerezyme (imiglucerase), a recombinant ERT manufactured using Chinese hamster ovary cells, which eliminated reliance on human-derived materials and improved purity and yield. Clinical data confirmed Cerezyme's noninferiority to Ceredase in restoring enzyme activity and alleviating symptoms, facilitating a seamless transition that sustained therapy access while reducing immunogenicity risks. This recombinant shift exemplified Genzyme's commitment to biotechnological refinement, paving the way for further orphan approvals like Fabrazyme (agalsidase beta) for Fabry disease in 2003 and Myozyme (alglucosidase alfa) for Pompe disease in 2006, each addressing unmet needs in substrate accumulation disorders through targeted ERT.[](https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/alglucerase-injection-ceredaser-gaucher-disease)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/)\n\nBy prioritizing patient registries, long-term outcome studies, and advocacy for regulatory flexibility, Genzyme under Termeer not only treated thousands but also influenced industry norms, proving that orphan drug investment could yield sustainable returnsâ€”exceeding $1 billion in annual revenue from its rare disease portfolio by 2010â€”while spurring competitors to enter the field and expanding treatment options for conditions previously managed palliatively.[](https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry)[](https://www.hbs.edu/faculty/Pages/item.aspx?num=28922)\n\n### Economic and Medical Impact\n\nGenzyme's orphan drug strategy yielded significant economic returns, with revenues totaling $4.1 billion in 2010, driven largely by high-margin therapies for rare diseases that benefited from limited competition and regulatory incentives under the Orphan Drug Act.[](https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/) This model supported a global workforce of approximately 10,000 employees engaged in research, manufacturing, and commercialization, concentrating economic activity in biotechnology hubs such as Boston, Massachusetts.[](https://www.news.sanofi.us/press-releases?item=118549) The approach validated the viability of investing in small patient populations, encouraging broader sector shifts toward rare disease-focused development and culminating in Genzyme's $20.1 billion acquisition by Sanofi in 2011, which enhanced Sanofi's specialty care portfolio and contributed to a 6.9% sales growth in the following year.[](https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/)[](https://www.prnewswire.com/news-releases/sanofi-sales-growth-of-69-thanks-to-genzyme-acquisition-and-performance-of-growth-platforms-126311908.html)\n\nOn the medical front, Genzyme's enzyme replacement therapies (ERTs) profoundly altered outcomes for patients with lysosomal storage disorders, conditions previously marked by progressive organ failure and early mortality. Imiglucerase (Cerezyme), approved in 1994 for type 1 Gaucher disease, reversed key pathologies including hepatosplenomegaly, anemia, thrombocytopenia, and skeletal deterioration, with long-term studies showing sustained reductions in bone pain, crises, and disease-related complications.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/)[](https://www.cerezyme.com/considering-cerezyme/clinical-studies) Similarly, agalsidase beta (Fabrazyme) for Fabry disease and alglucosidase alfa (Myozyme/Lumizyme) for Pompe disease mitigated cardiac, renal, and neuromuscular damage, extending survival and improving functional status in clinical cohorts where supportive care alone yielded poor prognoses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3564370/) These interventions established ERT as a cornerstone for managing enzyme deficiencies, enabling affected individualsâ€”often numbering in the hundreds or thousands worldwide per disorderâ€”to achieve stable health metrics absent prior therapeutic options.[](https://www.europeanpharmaceuticalreview.com/article/233622/enzyme-replacement-therapy-improving-outcomes-in-rare-disease/)\n\n### Strategic Acquisitions and Partnerships\n\nGenzyme strategically acquired smaller biotechnology firms to address manufacturing bottlenecks and broaden its therapeutic portfolio in rare diseases and oncology. In September 2001, it completed the acquisition of Novazyme Pharmaceuticals for $137.5 million payable in Genzyme stock, with potential additional payments of up to $87.5 million contingent on regulatory milestones for enzyme replacement therapies.[](https://www.marketwatch.com/story/genzyme-to-buy-novazyme-for-up-to-225-million) Novazyme's proprietary gene activation and ProCellEx plant cell expression technologies enabled Genzyme to achieve higher yields of recombinant enzymes, mitigating supply shortages for Cerezyme (imiglucerase) used in Gaucher disease treatment and facilitating the 2006 FDA approval of Myozyme (alglucosidase alfa) for Pompe disease.[](https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/) This move was particularly timely, as Genzyme faced production constraints from viral contamination incidents in its Allston, Massachusetts facility earlier that year.[](https://www.ftc.gov/news-events/news/press-releases/2004/01/ftc-closes-its-investigation-genzyme-corporations-2001-acquisition-novazyme-pharmaceuticals-inc)\n\nIn 2009, Genzyme diversified into oncology through the acquisition of Bayer HealthCare's portfolio of marketed oncology products, including Campath (alemtuzumab), a monoclonal antibody approved for B-cell chronic lymphocytic leukemia.[](https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm) The deal, valued at approximately $225 million plus royalties, allowed Genzyme to leverage its rare disease sales infrastructure for these specialized cancer therapies, generating over $100 million in annual Campath sales by 2010 while assuming Bayer's prior manufacturing and royalty obligations.[](https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm)\n\nGenzyme also pursued partnerships to access cutting-edge platforms in antisense and gene modulation technologies, accelerating pipeline development without full internal R\u0026D investment. In January 2008, it formed a strategic alliance with Isis Pharmaceuticals (now Ionis), securing exclusive worldwide rights to develop and commercialize mipomersen, an antisense drug targeting apoB to lower LDL cholesterol in high-risk cardiovascular patients, with an upfront payment of $175 million, $150 million in near-term R\u0026D funding, and potential milestones and royalties exceeding $1 billion.[](https://ir.ionis.com/news-releases/news-release-details/genzyme-and-isis-announce-strategic-alliance-including-exclusive) Phase III trials under this collaboration advanced mipomersen toward FDA review, though regulatory hurdles later emerged. Complementing this, Genzyme maintained ongoing collaborations with PTC Therapeutics on small-molecule splicing modifiers for rare genetic conditions like spinal muscular atrophy, initiated in the mid-2000s and restructured in 2011 to focus on lead candidates.[](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-genzyme-announce-restructuring) These alliances underscored Genzyme's approach to risk-sharing in high-cost biotech innovation, prioritizing orphan indications with limited competition.\n\n## Controversies and Criticisms\n\n### Manufacturing Contamination and Product Shortages (2009-2011)\n\n![Genzyme plant, Allston, Massachusetts](./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg)\n\nIn February 2009, the U.S. Food and Drug Administration (FDA) issued a warning letter to Genzyme regarding manufacturing deficiencies at its Allston, Massachusetts facility, highlighting issues with quality control and production processes for biologic drugs including Cerezyme and Fabrazyme.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/) These concerns predated the more severe disruptions that followed.\n\nOn June 16, 2009, Genzyme disclosed the detection of Vesivirus 2117, a non-human virus, in bioreactors at the Allston plant, which impaired cell growth and necessitated a shutdown of production for Cerezyme (imiglucerase), an enzyme replacement therapy for Gaucher disease, and Fabrazyme (agalsidase beta), a treatment for Fabry disease.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/) [](https://www.biopharminternational.com/view/genzyme-detects-virus-contamination-bioreactor-halts-production) The contamination affected multiple production batches, leading to immediate global shortages of these orphan drugs, as the Allston facility was the primary manufacturing site.[](https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/) Genzyme implemented dose rationing protocols, reducing patient allocations to 40-70% of standard levels to extend supplies, which impacted approximately 1,500 Cerezyme patients and fewer than 1,000 Fabrazyme patients worldwide.[](https://www.nytimes.com/2010/04/16/business/16genzyme.html)\n\nThe shortages resulted in reported adverse health effects among patients, including chronic pain, fatigue, muscle spasms, and cognitive impairments; one Fabry patient, William Schubert, died in March 2010 amid reduced dosing, though a direct causal link was not established.[](https://www.nytimes.com/2010/04/16/business/16genzyme.html) Genzyme's CEO Henri Termeer acknowledged the company's failure to maintain adequate reserves, attributing it partly to prioritization of production for Myozyme, a therapy for Pompe disease.[](https://www.nytimes.com/2010/04/16/business/16genzyme.html) Efforts to mitigate the crisis included accelerating production at alternative sites and importing limited supplies, with initial shipments of new Cerezyme resuming in December 2009 and Fabrazyme in January 2010, though at reduced volumes.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/)\n\nA subsequent FDA inspection from October to November 2009 uncovered additional violations, including particulate contaminationâ€”such as metal fragments, rubber, fibers, and glassâ€”in finished vials of Cerezyme, Fabrazyme, Myozyme, and Thyrogen, stemming from inadequate equipment maintenance and inspection processes in the aseptic filling operations.[](https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009) The agency issued Form 483 observations citing failures in deviation investigations and preventive measures, prompting Genzyme to discard affected batches.[](https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009)\n\nRegulatory pressure intensified in 2010, culminating in a May consent decree requiring Genzyme to pay a $175 million penalty, outsource filling and packaging, and implement FDA oversight at Allston; violations risked further shutdowns.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/) Despite these measures and production transfers to facilities in Ireland and Kansas by late 2010, shortages persisted into 2011, with limited Cerezyme supplies projected through January 2012 due to ongoing capacity constraints and quality issues.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/) [](https://www.bloomberg.com/news/articles/2011-09-15/sanofi-s-genzyme-sees-limited-cerezyme-supplies-through-january) The crisis contributed to a decline in Genzyme's revenue and stock value, exacerbating vulnerabilities ahead of its acquisition by Sanofi-Aventis.[](https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/)\n\n### Marketing Practices and Legal Settlements\n\nIn 2013, Genzyme Corporation agreed to pay $22.28 million to settle civil allegations under the False Claims Act that it promoted an unapproved \"slurry\" form of its Seprafilm adhesion barrier product, leading to the submission of false claims to federal and state healthcare programs for off-label uses not approved by the FDA.[](https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients) The settlement stemmed from whistleblower complaints alleging that Genzyme sales representatives distributed recipes and training materials to physicians on converting solid Seprafilm sheets into a liquid slurry for intra-abdominal applications, despite the product's labeling restricting it to solid-sheet use on serosal surfaces during surgery.[](https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients) This practice allegedly occurred between 2004 and 2009, with the company cooperating in the federal investigation but denying liability as part of the resolution.[](https://www.massdevice.com/whistleblower-lawsuit-costs-genzyme-22m/)\n\nThe Seprafilm controversy escalated in 2015 when Genzyme entered a deferred prosecution agreement with the U.S. Department of Justice, agreeing to pay an additional $32.5 million to resolve criminal charges related to the same off-label promotion and distribution of the slurry form.[](https://www.justice.gov/archives/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm) Under the agreement, Genzyme admitted that its employees had engaged in a scheme to promote the unapproved slurry despite internal policies prohibiting off-label promotion, including disseminating non-public information and materials to encourage its use.[](https://www.gibsondunn.com/wp-content/uploads/documents/publications/Genzyme-DPA-and-Attachments.pdf) The total penalties for the Seprafilm marketing issues exceeded $54 million, including state-level recoveries such as New Jersey's $102,000 share from alleged kickback schemes tied to the promotion.[](https://nj.gov/oag/newsreleases14/pr20140312a.html) These settlements highlighted compliance risks in promoting medical devices beyond FDA-approved indications, though Genzyme implemented remedial measures like enhanced training and monitoring post-resolution.[](https://ca.finance.yahoo.com/news/sanofis-genzyme-pays-32-59-million-criminal-seprafilm-000515813--finance.html)\n\nNo major additional settlements directly tied to off-label marketing of Genzyme's other products, such as its rare disease therapies, were identified in public records from the period, though the company faced broader scrutiny over sales practices amid its high pricing for orphan drugs.[](https://www.justice.gov/d9/press-releases/attachments/2015/09/03/genzyme_dpa_attachment_b.pdf) The Seprafilm cases were resolved without criminal charges against individuals, reflecting a focus on corporate accountability through monetary penalties and deferred prosecution rather than trial outcomes.[](https://news.bloomberglaw.com/white-collar-and-criminal-law/genzyme-to-pay-325m-for-false-marketing-of-seprafilm)\n\n### Patient Safety and Dosage Disputes\n\nIn response to manufacturing shortages of Fabrazyme (agalsidase beta), the enzyme replacement therapy for Fabry disease, the U.S. Food and Drug Administration (FDA) authorized reduced dosages starting in June 2010, initially at one-third of the standard 1 mg/kg biweekly dose, later increased to half in some cases, to extend limited supplies amid production issues at Genzyme's Allston, Massachusetts facility.[](https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020) Genzyme implemented a rationing program allocating approximately 0.3â€“0.5 mg/kg per infusion, prioritizing existing patients while deferring new ones, with internal documents later revealing company awareness that such reductions might not maintain therapeutic efficacy against progressive kidney, heart, and neurological damage.[](https://www.statnews.com/wp-content/uploads/2024/02/Genzyme-Fourth-Amended-Complaint.pdf)[](https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/)\n\nPatient advocacy groups and affected individuals contested the safety of these lower doses, arguing they failed to stabilize disease progression, leading to documented deteriorations such as worsening renal function and increased pain, as evidenced in clinical monitoring data from rationed patients.[](https://patentdocs.org/2011/03/10/fabry-patients-sue-genyzme-for-damages-caused-by-fabrazyme-rationing/)[](https://www.nature.com/articles/nm.2440.pdf) Multiple class-action lawsuits filed against Genzyme (later Sanofi post-2011 acquisition) alleged negligence in continuing reduced-dose distribution despite knowledge of inefficacy, with claims that the company diverted fuller supplies to Europe where shortages were less acute, potentially exacerbating U.S. patient harms.[](https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020)[](https://law.justia.com/cases/federal/appellate-courts/ca1/15-1446/15-1446-2016-05-23.html) A 2024 federal appeals court ruling revived key litigation, rejecting prior dismissals and allowing evidence on whether Genzyme misrepresented dose adequacy, though long-term studies on reduced dosing remain limited and contested, with some pharmacodynamic data suggesting partial benefit but not equivalence to full dosing.[](https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020)[](https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/)\n\nSimilar dosage debates arose with Cerezyme (imiglucerase) for Gaucher disease, where in 2008, amid high annual costs exceeding $200,000 per patient at standard 60 units/kg thrice weekly, the National Gaucher Foundation endorsed dose reductions to 15â€“30 units/kg based on retrospective analyses showing maintained hemoglobin and platelet stability in low-risk patients.[](https://www.nytimes.com/2008/03/16/business/16gaucher.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/) Genzyme countered that such cuts risked inadequate visceral and skeletal protection, citing phase III trial data establishing higher doses for optimal outcomes, though acknowledging no acute toxicity from reductions; unresolved questions persisted on minimal effective dosing, influenced by pharmacoeconomic pressures rather than definitive safety thresholds.[](https://www.nytimes.com/2008/03/16/business/16gaucher.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/) During 2009â€“2011 Cerezyme shortages, temporary dose tapering to every other week or lower amounts was again FDA-sanctioned, with post-shortage studies indicating transient biomarker worsening in some adults but no irreversible harms in monitored cohorts.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4289531/)[](https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf)\n\nThese disputes highlighted tensions between resource allocation during supply constraints and evidence-based dosing, with critics attributing Genzyme's stance to revenue preservationâ€”given orphan drug pricing dynamicsâ€”while company responses emphasized data-driven protocols to avert undertreatment risks, absent randomized trials conclusively proving low-dose equivalence for safety endpoints like organ preservation.[](https://www.nytimes.com/2008/03/16/business/16gaucher.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/) No regulatory findings deemed standard doses unsafe, but litigation outcomes remain pending for Fabrazyme claims, underscoring ongoing scrutiny of biotech firms' handling of rare disease therapy access.[](https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020)\n\n## Regulatory Engagement and Lobbying\n\n### Interactions with FDA and Other Agencies\n\nGenzyme Corporation's interactions with the U.S. Food and Drug Administration (FDA) primarily involved securing orphan drug designations and biologic license applications for enzyme replacement therapies targeting rare genetic disorders, leveraging incentives under the Orphan Drug Act of 1983 such as protocol assistance, tax credits, and seven-year market exclusivity.[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491) The FDA granted orphan designation for imiglucerase (Cerezyme) for Gaucher disease types I, II, and III, culminating in approval on May 23, 1994, marking Genzyme's first major therapeutic for a lysosomal storage disorder.[](https://purplebooksearch.fda.gov/productdetails?query=020367) Similarly, agalsidase beta (Fabrazyme) received orphan designation in 1998 and FDA approval on April 24, 2003, for Fabry disease, while alglucosidase alfa (Myozyme) was designated and approved on April 28, 2006, for Pompe disease, with both latter products carrying boxed warnings for anaphylaxis and hypersensitivity risks common to such therapies.[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=15286)[](https://go.drugbank.com/drugs/DB00103)[](https://www.drugs.com/history/myozyme.html)\n\nThese approvals often followed priority or accelerated review pathways due to the orphan status and unmet needs in rare diseases, reflecting collaborative pre-approval consultations between Genzyme and FDA on clinical trial designs and manufacturing scales.[](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597) Post-approval, interactions included FDA oversight of adverse event reporting and labeling updates, such as enhanced warnings for immune-mediated reactions in enzyme replacement therapies.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf)\n\nRegulatory enforcement formed another key facet, particularly following FDA inspections of Genzyme's Allston, Massachusetts, facility that identified current good manufacturing practice violations, including equipment contamination risks. On May 24, 2010, Genzyme signed a consent decree of permanent injunction with the FDA and Department of Justice, requiring a $175 million disgorgement of profits, submission of a detailed remediation timetable (initially proposed in October 2009), independent audits, and FDA approval for resuming full production.[](https://www.govinfo.gov/content/pkg/USCOURTS-mad-1_09-cv-11299/pdf/USCOURTS-mad-1_09-cv-11299-0.pdf) By November 2010, Genzyme met initial milestones under the decree, including facility upgrades, though full compliance extended into subsequent years.[](https://www.fiercebiotech.com/biotech/genzyme-successfully-meets-first-milestones-of-fda-consent-decree)\n\nBeyond the FDA, Genzyme engaged with the European Medicines Agency (EMA) for parallel authorizations, such as Myozyme's approval in March 2006 ahead of its U.S. counterpart, and EMA validation of the Framingham, Massachusetts, plant in January 2012 to support expanded supply.[](https://www.biospace.com/fda-approves-genzyme-corporation-s-myozyme-r-for-all-patients-with-pompe-disease-drug-to-carry-warning) These multinational interactions underscored Genzyme's navigation of harmonized standards under the International Conference on Harmonisation while addressing agency-specific requirements for orphan medicinal products.[](https://www.fiercepharma.com/pharma/genzyme-announces-european-approval-of-framingham-manufacturing-plant)\n\n### Advocacy on Intellectual Property and Orphan Drug Policies\n\nGenzyme, under the leadership of CEO Henri Termeer, actively advocated for policies that bolstered incentives under the U.S. Orphan Drug Act of 1983, emphasizing the necessity of market exclusivity and tax credits to offset the high development costs for treatments of rare diseases affecting fewer than 200,000 individuals in the United States.[](https://www.pharmexec.com/view/genzyme-price-success) The company's flagship enzyme replacement therapies, such as Ceredase (approved in 1991) and its successor Cerezyme (approved in 1994), directly benefited from the Act's seven-year market exclusivity provisions, which Genzyme defended as essential to recouping investments in niche markets with limited patient populations.[](https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry) Termeer argued that without such protections, pharmaceutical firms would lack economic motivation to pursue orphan drug development, a stance he articulated in congressional testimony opposing proposed price caps on these therapies during the 1990s, when critics highlighted escalating costs like Cerezyme's annual price exceeding $300,000 per patient.[](https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html)\n\nIn response to challenges threatening exclusivity, Genzyme resisted efforts to compel technology transfer or generic production during supply shortages, such as the 2009-2011 contamination crises affecting Cerezyme and Fabrazyme. Patients petitioned the National Institutes of Health in 2011 to intervene and mandate Genzyme share manufacturing processes with competitors, but the company maintained that undermining exclusivity would deter future innovation in rare disease treatments by eroding the financial viability of such endeavors.[](https://www.nature.com/articles/nm0511-522b) This position aligned with broader industry lobbying to preserve the Orphan Drug Act's framework against reforms aimed at curbing perceived abuses, including multiple orphan designations for the same drug across indications to extend effective exclusivity periods beyond seven yearsâ€”a strategy Genzyme employed but which drew scrutiny for potentially inflating prices without proportional public health benefits.[](https://sourceonhealthcare.org/orphan-drug-act-fostering-innovation-or-abuse/)\n\nOn intellectual property fronts intertwined with orphan policies, Genzyme supported robust patent protections for biotechnological innovations, viewing them as complementary to regulatory exclusivities in sustaining R\u0026D for complex enzyme therapies. In European contexts, the company invoked protections under EU Regulation 141/2000, which grants 10-year orphan drug exclusivity, to defend against competitive challenges, as evidenced in a 2004 UK Competition Appeal Tribunal ruling acknowledging the specialized nature of orphan drug rights in limiting market entry.[](https://www.catribunal.org.uk/sites/cat/files/Jdg1016Genzy110304.pdf) Termeer-era advocacy extended to international forums, promoting similar incentive structures globally to encourage neglected disease research, though Genzyme prioritized maintaining U.S. and EU safeguards amid growing debates over high pricing and access.[](https://www.biospace.com/genzyme-corporation-launches-initiative-to-assist-the-development-of-treatments-for-neglected-diseases) These efforts underscored Genzyme's view that strong IP and orphan-specific policies were causally linked to the Act's success in spurring over 2,000 orphan designations by the early 2010s, transforming previously untreatable conditions into manageable ones despite criticisms of monopolistic pricing dynamics.[](https://academic.oup.com/shm/article/32/3/609/4663001)\n\n## Post-Acquisition Legacy\n\n### Integration into Sanofi\n\nSanofi completed its acquisition of Genzyme on April 8, 2011, following shareholder approval and regulatory clearances, for a total enterprise value of approximately $20.1 billion, or $74 per share in cash.[](https://www.prnewswire.com/news-releases/sanofi-aventis-completes-acquisition-of-genzyme-corporation-119496769.html)[](https://www.news.sanofi.us/press-releases?item=118549) Immediately after the February 2011 announcement, the companies formed a joint Integration Steering Committee to oversee the process, focusing on operational alignment while preserving Genzyme's biotechnology expertise.[](https://www.news.sanofi.us/press-releases?item=118549) Genzyme's rare disease business was initially structured as a stand-alone division within Sanofi, retaining the Genzyme brand to maintain continuity in its specialized operations and patient-focused model.[](https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm)\n\nBy mid-2011, Sanofi implemented changes to integrate Genzyme's functions, including a new reporting structure for marketing and sales units and coordination of R\u0026D programs under an umbrella Sanofi Oncology unit to leverage synergies in biotechnology and therapeutic development.[](https://www.fiercepharma.com/pharma/sanofi-moves-deeper-into-genzyme-operations)[](https://www.boston.com/uncategorized/noprimarytagmatch/2011/06/14/sanofi-putting-its-stamp-on-genzyme/) Sanofi's leadership described the 2011 integration as successful, noting contributions to overall revenue growth from Genzyme's platforms in rare diseases and multiple sclerosis treatments.[](https://www.news.sanofi.us/press-releases?item=121274) This phase emphasized retaining Genzyme's autonomous operations in key areas, such as its Framingham, Massachusetts headquarters, to avoid disrupting ongoing clinical and manufacturing activities amid prior contamination issues.[](https://www.news.sanofi.us/press-releases?item=118549)\n\nIn July 2015, Sanofi reorganized its global business units, establishing the Specialty Care Global Business Unit as \"Sanofi Genzyme,\" led by David Meeker, former Genzyme president, encompassing rare diseases, multiple sclerosis, immunology, and oncology portfolios to drive focused growth in high-value therapeutics.[](https://www.europeanpharmaceuticalreview.com/news/33346/sanofi-announces-new-global-business-unit-structure/) This structure integrated Genzyme's assets more deeply into Sanofi's specialty care strategy, combining them with complementary products like multiple sclerosis drug Aubagio while maintaining dedicated rare disease expertise.[](https://www.fiercepharma.com/pharma/sanofi-announces-new-global-business-unit-structure-to-drive-future-growth)\n\nBy February 2022, Sanofi completed full integration of the Sanofi Genzyme entity into its broader Specialty Care division, discontinuing the separate Genzyme branding after 11 years to streamline operations and unify its rare disease and specialty portfolio under a single corporate identity.[](https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/) This culminated the multi-year integration, with Genzyme's legacy productsâ€”such as Cerezyme for Gaucher disease and Fabrazyme for Fabry diseaseâ€”continuing under Sanofi's oversight, contributing to sustained revenue from orphan drugs exceeding expectations set at acquisition.[](https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/) Post-2022, no major structural reversals occurred, with the integrated unit supporting Sanofi's emphasis on biologics and gene therapies through 2025.[](https://www.news.sanofi.us/press-releases?item=121274)\n\n### Ongoing Influence and Recent Developments (2011-2025)\n\nFollowing its acquisition by Sanofi on April 8, 2011, Genzyme's rare disease franchises drove substantial revenue growth for the parent company, with integration efforts yielding double-digit expansion in growth platforms by 2012.[](https://www.news.sanofi.us/press-releases?item=121274) The deal positioned Genzyme as a core biotechnology pillar, enhancing Sanofi's capabilities in enzyme replacement therapies and orphan drugs while addressing prior manufacturing vulnerabilities through combined resources.[](https://www.news.sanofi.us/press-releases?item=118549)\n\nGenzyme operated initially as a semi-autonomous unit under its brand, preserving operational continuity in treatments for lysosomal storage disorders such as Gaucher disease (Cerezyme) and Fabry disease (Fabrazyme), which continued to generate sustained sales amid resolved supply chain issues from pre-acquisition shortages.[](https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm) This structure facilitated R\u0026D acceleration, including biomarker-driven expansions for legacy assets like Campath (alemtuzumab), repurposed for specific patient subsets post-merger.[](https://www.fiercebiotech.com/biotech/post-merger-genzyme-opens-up-throttle-on-r-d-plans)\n\nBy 2022, Sanofi phased out the Genzyme name from its specialty care division after 11 years, signaling full strategic integration while maintaining the underlying portfolio's influence on rare disease strategy.[](https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/) The legacy endures through Sanofi's ongoing commercialization of Genzyme-originated therapies, including approvals and expansions for Pompe disease (Myozyme/Lumizyme) and mucopolysaccharidosis I (Aldurazyme), which remain foundational to the company's rare disease revenue exceeding expectations set at acquisition.[](https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/)[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases)\n\nRecent advancements build on this foundation, with Sanofi leveraging Genzyme's expertise in 2020 via the Principia Biopharma acquisition to extend into immune-mediated rare blood disorders like chronic immune thrombocytopenia, incorporating targeted oral therapies alongside traditional enzyme replacements.[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-blood-disorders) As of 2025, the rare diseases pipelineâ€”encompassing 86 projects across immunology, neurology, and oncology intersectionsâ€”incorporates RNAi therapeutics and nanobody platforms to address unmet needs in hemophilia and other inherited disorders, reflecting evolved causal mechanisms from Genzyme's enzyme-focused origins.[](https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf)[](https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development) Sanofi's rilzabrutinib, advancing for rare autoimmune conditions, exemplifies this progression toward manageable chronic diseases, with real-world data underscoring persistent efficacy of integrated legacy products.[](https://www.pharmalive.com/sanofi-2025-from-the-incurable-to-the-manageable/)"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761885660397,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"FACTBOX-Key facts about Sanofi and Genzyme - Reuters\",\"description\":\"Feb 16, 2011 Â· Genzyme was founded in 1981 by Henry Blair, an enzymologist who had been collaborating with the National Institutes of Health (NIH) to develop aÂ ...Missing:  Corporation | Show results with:Corporation\",\"url\":\"https://www.reuters.com/article/2011/02/16/sanofi-genzyme-facts-idUSLDE71F0HY20110216/\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Genzyme Incorporated - National Science and Technology Medals ...\",\"description\":\"The company started by Henry Blair to develop enzyme therapies was bought in 2011 by French pharmaceutical company, Sanofi, for $20 billion in 2011. SanofiÂ ...Missing:  achievements acquisition\",\"url\":\"https://nationalmedals.org/laureate/genzyme-incorporated/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Building on a legacy of enzyme replacement therapy to fuel rare ...\",\"description\":\"Jan 30, 2020 Â· That work began some 35 years ago when the biotech pioneer Genzyme, now a part of Sanofi, discovered its first rare disease treatments.\",\"url\":\"https://www.statnews.com/sponsor/2020/01/30/building-on-a-legacy-of-enzyme-replacement-therapy-to-fuel-rare-disease-treatment/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Small Audience, Large Payoff - C\u0026EN - American Chemical Society\",\"description\":\"May 13, 2013 Â· Genzyme made its mark by introducing the first treatment for Gaucher's disease, a lysosomal storage disease caused by a deficiency in the lipidÂ ...Missing:  achievements | Show results with:achievements\",\"url\":\"https://cen.acs.org/articles/91/i19/Small-Audience-Large-Payoff.html\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"History of Genzyme Corporation - FundingUniverse\",\"description\":\"In 1994, Genzyme received FDA approval to market Cerezyme, a genetically engineered replacement for Ceredase. The company also hoped to benefit from Orphan ActÂ ...\",\"url\":\"https://www.fundinguniverse.com/company-histories/genzyme-corporation-history/\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Henri: N of 1 - BioCentury\",\"description\":\"May 20, 2017 Â· Henry Blair, one of Genzyme's founders and a scientist at Tufts University, brought the start-up a contract to supply glucocerebrosidase toÂ ...\",\"url\":\"https://www.biocentury.com/article/286818/how-the-late-genzyme-ceo-henri-termeer-created-the-orphan-drug-industry\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"A Flair for the Business of Medicine | Tufts Now\",\"description\":\"Apr 12, 2012 Â· The company's signature product, Cerezyme, is a cure for Gaucher's (go-SHAY) disease that costs patients up to $200,000 a year. Last spring, onÂ ...\",\"url\":\"https://now.tufts.edu/2012/04/12/flair-business-medicine\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share ...\",\"description\":\"Feb 16, 2011 Â· Sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion(1).\",\"url\":\"https://www.news.sanofi.us/press-releases?item=118549\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Imiglucerase in the treatment of Gaucher disease: a history and ...\",\"description\":\"Thereafter, Genzyme was forced temporarily to close its Allston plant, leading to the severe shortages of Cerezyme (and Fabrazyme for Fabry disease). In theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3340106/\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"How a 15-year-old Genzyme drug shortage became a legal ...\",\"description\":\"Feb 26, 2024 Â· A manufacturing problem from 15 years ago and the resulting prolonged drug shortage is at the heart of newly revived litigation against Sanofi's Genzyme.Missing:  key | Show results with:key\",\"url\":\"https://www.pharmavoice.com/news/genzyme-fabrazyme-drug-shortage-lawsuit/708417/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"WILKINS v. GENZYME CORPORATION (2024) - FindLaw Caselaw\",\"description\":\"Feb 15, 2024 Â· They allege that Genzyme knew that low-dose Fabrazyme would not effectively treat Fabry disease and yet continued to sell the reduced doses toÂ ...\",\"url\":\"https://caselaw.findlaw.com/court/us-1st-circuit/115829215.html\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Genzyme Corporation was founded in Boston, Mass - Life Science\",\"description\":\"In 2011, Sanofi-aventis acquired Genzyme for $74 a share in cash or $21.1 billion. Tags: China. Source: Sanofi Credit: Visit News/History Source.Missing:  achievements acquisition\",\"url\":\"https://lifesciencehistory.com/genzyme-corporation-was-founded-in-boston-mass/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Genzyme Corporation - Company-Histories.com\",\"description\":\"Enzyme Technology in the Early 1980s. In 1981, Henry Blair founded Genzyme to produce products based on enzyme technologies. With the help of venture capitalÂ ...\",\"url\":\"https://www.company-histories.com/Genzyme-Corporation-Company-History.html\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"ERT Approval Anniversary | Gaucher Disease Blog\",\"description\":\"In 1981, Blair and Termeer founded Genzyme to begin producing the enzyme in quantities needed for clinical trials. The First Clinical Trials. In 1983, DrÂ ...Missing:  Corporation early\u003c|separator|\u003e\",\"url\":\"https://www.gaucherdisease.org/blog/25th-anniversary-fda-approval-ert/\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Search Orphan Drug Designations and Approvals - FDA\",\"description\":\"1, Generic Name: Alglucerase injection. Trade Name: Ceredase. Marketing Approval Date: 04/05/1991. Approved Labeled Indication: Long-term enzyme replacementÂ ...\",\"url\":\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=5585\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"[PDF] Genzyme's Focus on Orphan Drugs - SweetStudy\",\"description\":\"Genentech was the oldest, formed in 1976; Amgen, Chiron, and Genzyme were established in the early 1980s. The remaining competitors were small, emergingÂ ...\",\"url\":\"https://www.sweetstudy.com/sites/default/files/q4/08/06/genzymes_focus_on_orphan_drugs.pdf\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"Purple Book Database of Licensed Biological Products\",\"description\":\"Cerezyme, Rx. Proper Name imiglucerase. BLA Number 020367. Applicant Genzyme Corporation. Original Approval Date May 23, 1994. Date of First Licensure. ReturnÂ ...\",\"url\":\"https://purplebooksearch.fda.gov/productdetails?query=020367\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Genzyme begins expansion of Boston manufacturing plant\",\"description\":\"Genzyme began construction of Allston Landing in the early 1990s, and the facility was initially intended to produce one product â€“ Cerezyme (imigluceraseÂ ...\",\"url\":\"https://www.reliableplant.com/Read/8334/genzyme-begins-expansion-of-boston-manufacturing-plant\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Genzyme Manufacturing Expansion - Pharmaceutical Technology\",\"description\":\"Dec 17, 2009 Â· The Allston Landing facility opened in 1996 and produces five different drugs. Cerezyme is one of Genzyme's bestselling drugs, and the newÂ ...Missing:  1990s | Show results with:1990s\",\"url\":\"https://www.pharmaceutical-technology.com/uncategorized/ganzymemanufacturing/\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"GENZYME REPORTS PROFITS OF $14M FOR 1994 + - BioWorld\",\"description\":\"Mar 3, 1995 Â· Revenues for 1994 totaled $310.7 million, an increase of 17 percentover 1993's $265.7 million. Net income for the year, before specialcharges,Â ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.bioworld.com/articles/396653-genzyme-reports-profits-of-14m-for-1994\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Genzyme's Seprafilm gets FDA marketing nod - Nature\",\"description\":\"Genzyme's Seprafilm gets FDA marketing nod. The first biodegrad- able ... ed and approved for marketing in the. United States on March 25, 1996 by aÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.nature.com/articles/nbt0596-572a.pdf\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"FDA Approves Genzyme's Carticel for Cartilage Repair + - BioWorld\",\"description\":\"Aug 26, 1997 Â· Carticel was launched in 1995, but at the time, the agency had no regulations regarding autologous cell therapies. After an initial safetyÂ ...\",\"url\":\"https://www.bioworld.com/articles/364972-fda-approves-genzyme-s-carticel-for-cartilage-repair\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Genzyme to Acquire Novazyme Pharmaceuticals - AMDA-Pompe.org\",\"description\":\"Aug 7, 2001 Â· Genzyme was the first to successfully employ protein remodeling technology in the 1980s when it used a different process to produce CeredaseÂ® (Â ...\",\"url\":\"https://amda-pompe.org/genzyme-to-acquire-novazyme-pharmaceuticals/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"List of biotech, pharma \u0026 medical device company acquisitions\",\"description\":\"Acquired by The Medicines Company, Feb 2015. Add'l Locations Annovis, Acquired by Transgenomic, May 2001. Add'l Locations AnorMED, Acquired by Genzyme, Oct 2006.\",\"url\":\"https://biopharmguy.com/links/company-by-name-acquisitions.php\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"[PDF] Genzyme Corporation 2004 Annual Report - SEC.gov\",\"description\":\"Dec 31, 2004 Â· Financial results confirm strategy. Our strategy of diversification across five important and clearly defined medical areas and ourÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/vprr/0505/05050784.pdf\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"For Immediate Release - SEC.gov\",\"description\":\"Jan 9, 2007 Â· Genzyme's performance in 2006 caps a six-year period in which sales have increased at a compound annual rate of approximately 27 percent, drivenÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/732485/000110465907001467/a07-1497_1ex99d1.htm\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"Genzyme Reports Financial Results for the Second Quarter of 2010\",\"description\":\"Jul 21, 2010 Â· Total 2010 revenue is expected to be $4.4 billion - $4.5 billion. Non-GAAP EPS is expected to be $0.40 - $0.50 per diluted share in the thirdÂ ...Missing:  2000-2010 | Show results with:2000-2010\",\"url\":\"https://www.fiercebiotech.com/biotech/genzyme-reports-financial-results-for-second-quarter-of-2010\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"genzyme corporation - SEC.gov\",\"description\":\"We manufacture Cerezyme and Fabrazyme at our multi-product manufacturing facility in Allston, Massachusetts. This facility, which we own and which containsÂ ...Missing:  key | Show results with:key\u003c|separator|\u003e\",\"url\":\"https://www.sec.gov/Archives/edgar/data/732485/000104746904007949/a2129500z10-k.htm\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Key dates in Genzyme's manufacturing crisis | Reuters\",\"description\":\"Aug 13, 2010 Â· The manufacturing crisis has punished Genzyme's earnings and share price and made it more vulnerable to dissident investors.Missing:  1981-1989 | Show results with:1981-1989\",\"url\":\"https://www.reuters.com/article/business/healthcare-pharmaceuticals/key-dates-in-genzymes-manufacturing-crisis-idUSN13212528/\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Genzyme Halts Production of Two Drugs - The New York Times\",\"description\":\"Jun 16, 2009 Â· The company is closing a contaminated plant to clean it, which will cause a shortage in August of Cerezyme.Missing:  manufacturing | Show results with:manufacturing\",\"url\":\"https://www.nytimes.com/2009/06/17/business/17drug.html\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Genzyme Corp. Signs Consent Decree to Correct Violations at ...\",\"description\":\"May 25, 2010 Â· Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its Allston, Mass., manufacturing facility.Missing:  issues | Show results with:issues\",\"url\":\"https://www.fiercepharma.com/pharma/genzyme-corp-signs-consent-decree-to-correct-violations-at-allston-mass-manufacturing-plant\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Genzyme faces $175m FDA fines - SCI\",\"description\":\"A series of manufacturing problems has led to a shortage of the drugs since June 2009. At first, Genzyme's production site in Allston Landing in the US wasÂ ...\",\"url\":\"https://www.soci.org/chemistry-and-industry/cni-data/2010/9/genzyme-faces-175m-fda-fines\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Genzyme Corporation Case Analysis - 981 Words - Cram\",\"description\":\"During 2009 and 2010 Genzyme had to confront for many obstacles. Genzyme had a series of manufacturing problems which led to decline in sales of their main twoÂ ...Missing:  history 2000-2010 diversification\",\"url\":\"https://www.cram.com/essay/Analysis-Of-Enzyme-Corporation/PKHMCUAZ7BQQ\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Press Release - SEC.gov\",\"description\":\"Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has submitted a non-binding proposal to acquire Genzyme (NASDAQ: GENZ) in an all-cashÂ ...Missing:  merger | Show results with:merger\",\"url\":\"https://www.sec.gov/Archives/edgar/data/1121404/000119312510200153/dex991.htm\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Sanofi to buy Genzyme for more than $20 billion | Reuters\",\"description\":\"Feb 16, 2011 Â· French drugmaker Sanofi-Aventis SA clinched its long-sought deal for Genzyme Corp with a sweetened $20.1 billion cash offer, plus paymentsÂ ...Missing:  details | Show results with:details\",\"url\":\"https://www.reuters.com/article/world/sanofi-to-buy-genzyme-for-more-than-20-billion-idUSTRE71E4XI/\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Sanofi/Genzyme deal makes consent decree a mere detail\",\"description\":\"Feb 16, 2011 Â· \\\"Regulatory actions including consent decrees are increasingly part of the cost of business,\\\" says Jim Prutow, a partner in PRTM's healthcareÂ ...Missing:  merger approval integration\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.fiercepharma.com/manufacturing/sanofi-genzyme-deal-makes-consent-decree-a-mere-detail\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"[PDF] Case No COMP/M.5999 - SANOFI-AVENTIS/ GENZYME\",\"description\":\"Jan 12, 2011 Â· Merger Regulation sole control of the undertaking Genzyme Corporation (\\\"Genzyme\\\",. US), by way of public bid. I. THE PARTIES. 2. SanofiÂ ...Missing:  integration | Show results with:integration\",\"url\":\"https://ec.europa.eu/competition/mergers/cases/decisions/m5999_20110112_20310_2550120_EN.pdf\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Sanofi-Aventis Completes Acquisition of Genzyme Corporation\",\"description\":\"Apr 8, 2011 Â· As previously announced sanofi-aventis then effected, without a vote or meeting of Genzyme stockholders, a short-form merger on April 8, 2011 toÂ ...\",\"url\":\"https://www.fiercepharma.com/pharma/sanofi-aventis-completes-acquisition-of-genzyme-corporation\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Sanofi-Aventis completes acquisition of Genzyme Corporation\",\"description\":\"Apr 8, 2011 Â· As previously announced sanofi-aventis then effected, without a vote or meeting of Genzyme stockholders, a short-form merger on April 8, 2011 toÂ ...Missing:  details | Show results with:details\",\"url\":\"https://www.europeanpharmaceuticalreview.com/news/6539/sanofi-aventis-completes-acquisition-of-genzyme-corporation/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Sanafi Picks Up Genzyme for $20 Billion - NPR\",\"description\":\"Feb 17, 2011 Â· French drugmaker Sanofi-Aventis is buying Massachusetts-based Genzyme for more than $20 billion. The acquisition gives Sanofi a foothold in the increasinglyÂ ...\",\"url\":\"https://www.npr.org/2011/02/17/133831825/Sanafi-Picks-Up-Genzyme-for-20-Billion\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share ...\",\"description\":\"Feb 16, 2011 Â· Sanofi-aventis' acquisition of Genzyme has already received anti-trust clearance from the European Commission and the United States FederalÂ ...\",\"url\":\"https://www.prnewswire.com/news-releases/sanofi-aventis-to-acquire-genzyme-for-7400-in-cash-per-share-plus-contingent-value-right-116291094.html\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share ...\",\"description\":\"Feb 16, 2011 Â· Sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion1. In addition to the cash payment, each Genzyme shareholderÂ ...Missing:  details | Show results with:details\",\"url\":\"https://www.fiercebiotech.com/biotech/sanofi-aventis-to-acquire-genzyme-for-74-00-cash-per-share-plus-contingent-value-right\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"genzyme corporation - SEC.gov\",\"description\":\"Continuation of Genzyme legacy within Sanofi-Aventis: Genzyme's orphan disease business would be managed as a stand-alone division under the Genzyme brand, withÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/732485/000104746910008489/a2200413zsc14d9.htm\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Eleven years after buying Genzyme, Sanofi officially ditches ...\",\"description\":\"Feb 3, 2022 Â· Until the early 1980s, traditional drug makers didn't spend much time or money on diseases that affect relatively few people. Instead, theyÂ ...\",\"url\":\"https://www.statnews.com/2022/02/03/sanofi-genzyme-boston-name/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand ...\",\"description\":\"Oct 16, 2013 Â· Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand Manufacturing Capacity for FabrazymeÂ® Tuesday, October 15,Â ...\",\"url\":\"https://www.fiercepharma.com/manufacturing/genzyme-to-invest-80-million-framingham-mass-site-to-expand-manufacturing-capacity\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Our Manufacturing and Supply Chain Network | Sanofi\",\"description\":\"Our award-winning site in Framingham, MA is among the world's first digitally enabled facilities to use continuous-biologics-production technology. Its end-to-Â ...\",\"url\":\"https://www.sanofi.com/en/our-science/manufacturing-and-supply\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Virus stalls Genzyme plant | Nature Biotechnology\",\"description\":\"With sales of $1.2 billion for Cerezyme and $494 million for Fabryzyme in 2008, analysts estimate the manufacturing crisis will result in $100â€“300 million inÂ ...\",\"url\":\"https://www.nature.com/articles/nbt0809-681a\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Genzyme Corporation Surrenders $175 Million for Violations at ...\",\"description\":\"May 25, 2010 Â· 8, 2009, until Nov. 13, 2009, FDA inspectors found that the company's systems for ensuring manufacturing quality were inadequate resultingÂ ...\",\"url\":\"https://www.biospace.com/genzyme-corporation-surrenders-175-million-for-violations-at-mass-facility\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"National Resilience takes over Genzyme/Sanofi building in Allston\",\"description\":\"Mar 22, 2021 Â· National Resilience, a new life sciences startup, will take over the lease on the Sanofi Building, the former Genzyme plant on Soldiers Field Road in Allston.\",\"url\":\"https://news.harvard.edu/gazette/story/2021/03/national-resilience-takes-over-genzyme-sanofi-building-in-allston/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Operational Strategies for Managing Supply Chain Disruption Risk\",\"description\":\"The Genzyme experience captures the essence of the diversified supply strat- egy.7 By splitting production (or sourcing) across multiple facilities (orÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118115800.ch4\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"FDA Warns Sanofi of Manufacturing Irregularities at Key Facility\",\"description\":\"Jan 29, 2025 Â· On Jan. 15, 2025, a warning letter was sent to Sanofi stating that FDA inspectors found irregularities with the facility's bioreactor, theÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.dermatologyadvisor.com/news/fda-warns-sanofi-of-manufacturing-irregularities-at-key-facility/\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Sanofi gets FDA warning letter for Genzyme plant, supply chain ...\",\"description\":\"The FDA has issued a warning letter to Sanofi's Genzyme facility in Framingham, Massachusetts, citing multiple manufacturing violations.\",\"url\":\"https://www.pharmamanufacturing.com/industry-news/news/55262524/sanofi-gets-fda-warning-letter-for-genzyme-plant-supply-chain-remains-unaffected\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Resilience strategies for complex supply chains: Sanofi Genzyme\",\"description\":\"Jul 1, 2020 Â· Sanofi Genzyme is a pharmaceutical and biotechnology company focused on rare diseases, multiple sclerosis, immunology and oncology.\",\"url\":\"https://www.aboutresilience.com/resilience-strategies-for-complex-supply-chains/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Genzyme Manufacturing Expansion, Waterford - Pharmaceutical Technology\",\"description\":\"### Summary of Genzyme's Operations in Ireland\",\"url\":\"https://www.pharmaceutical-technology.com/projects/genzyme-ireland/\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Genzyme Reports Financial Results for the First Quarter of 2010\",\"description\":\"Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009Â ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/732485/000115752310002162/a6257774-ex991.htm\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Our Company - Sanofi U.S.\",\"description\":\"Quick Facts ; 13,000+. employees in the U.S. workforce ; 100,000+. employees in the global workforce ; 100. countries where Sanofi has a presenceÂ ...Missing:  Genzyme | Show results with:Genzyme\",\"url\":\"https://www.sanofi.us/en/our-company\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Sanofi Genzyme: Headquarters, Global Offices \u0026 Leadership Team\",\"description\":\"Framingham, Massachusetts, USA. Address: Sanofi, 1 The Mountain Road, Framingham, MA 01701 (One of several Sanofi sites in Framingham) Â· Waterford, Ireland Â· LyonÂ ...\",\"url\":\"https://www.highperformr.ai/company/sanofigenzyme\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Exhibit 99.3 - SEC.gov\",\"description\":\"Apr 28, 2011 Â· Today, approximately 10,000 Genzyme employees serve patients in nearly 100 countries. Genzyme's products are focused on rare inheritedÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/1121404/000119312511115014/dex993.htm\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Rare Diseases - Sanofi\",\"description\":\"We are proud to have launched groundbreaking medicines for Gaucher disease, Pompe disease, Fabry disease, mucopolysaccharidosis I (MPS I) and acidÂ ...\",\"url\":\"https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Search Orphan Drug Designations and Approvals - FDA\",\"description\":\"Generic Name: Imiglucerase. Trade Name: Cerezyme. Date Designated: 11/05/1991. Orphan Designation: Replacement therapy in patients with types I, II,Â ...\",\"url\":\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=62491\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"CEREZYMEÂ® (imiglucerase) for injection, for intravenous use ...\",\"description\":\"12.1 Mechanism of Action. Gaucher disease is characterized by a deficiency of Î²-glucocerebrosidase activity, which results in accumulation of glucocerebrosideÂ ...\",\"url\":\"https://products.sanofi.us/cerezyme/cerezyme.html\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Agalsidase beta: Uses, Interactions, Mechanism of Action - DrugBank\",\"description\":\"Jun 13, 2005 Â· Agalsidase beta was granted FDA approval on 24 April 2003. Modality: Protein Based Therapies Recombinant Enzymes; Groups: Approved,Â ...\",\"url\":\"https://go.drugbank.com/drugs/DB00103\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Fabrazyme is the only FDA-approved enzyme ... - Sanofi US News\",\"description\":\"Mar 12, 2021 Â· Fabrazyme is the only FDA-approved enzyme replacement therapy for Fabry disease with long-term efficacy and safety data.\",\"url\":\"https://www.news.sanofi.us/2021-03-12-Long-term-data-on-Fabrazyme-R-agalsidase-beta-for-people-with-Fabry-disease\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Myozyme (alglucosidase alfa) FDA Approval History - Drugs.com\",\"description\":\"FDA Approved: Yes (First approved April 28, 2006) ; Brand name: Myozyme ; Generic name: alglucosidase alfa ; Company: Genzyme Corp. ; Treatment for: Pompe Disease.\",\"url\":\"https://www.drugs.com/history/myozyme.html\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Search Orphan Drug Designations and Approvals - FDA\",\"description\":\"Marketing approved: ; 04/28/2006 Â· Myozyme for use in patients with Pompe disease (GAA deficiency).\",\"url\":\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=106597\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Enzyme replacement therapy with laronidase (AldurazymeÂ®) for ...\",\"description\":\"This article is an update of \\\"Enzyme replacement therapy with laronidase (Aldurazyme(Â®)) for treating mucopolysaccharidosis type I.\\\" in volume 4 on pageÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6581069/\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Our Products - Genzyme\",\"description\":\"SynviscÂ® (hylan G-F 20) is a local therapy that provides lubrication for the knee joint and can help reduce or stop pain in an osteoarthritic knee. CarticelÂ® (Â ...\",\"url\":\"https://www.genzymebiosurgery.com/our-products/\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"SYNVISC ONEÂ® HYLAN G-F 20 Prescribing Information\",\"description\":\"Synvisc-One is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservativeÂ ...Missing:  Renagel | Show results with:Renagel\",\"url\":\"https://products.sanofi.us/synviscone/synviscone.html\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Genzyme Corporation (Nasdaq - SEC.gov\",\"description\":\"Genzyme achieved strong sales growth in its three largest productsâ€”CerezymeÂ® (imiglucerase for injection), RenagelÂ® (sevelamer hydrochloride), and FabrazymeÂ® (Â ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/732485/000104746904012081/a2133569zex-99_1.htm\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Genzyme's Hylastan Fizzles; Synvisc-One Efforts Continue - BioWorld\",\"description\":\"Jul 6, 2007 Â· ... Renagel (sevelamer hydrochloride), the phosphate binder for kidney failure. Renagel sold $515 million in 2006, a number that Genzyme expectsÂ ...\",\"url\":\"https://www.bioworld.com/articles/452280\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Certain Genzyme Products for Rare Disorders Potentially ...\",\"description\":\"Nov 16, 2009 Â· The products, including Cerezyme, Fabrazyme, Myozyme, and Thyrogen (each supplied as lyophilized powders), as well as Aldurazyme (a liquidÂ ...\",\"url\":\"https://www.medscape.com/viewarticle/712448\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Our Product Pipeline | Sanofi\",\"description\":\"With a strong focus on difficult-to-treat diseases and immunization, our R\u0026D pipeline includes 93 clinical-stage projects*, 36 of which are in phase 3 or haveÂ ...\",\"url\":\"https://www.sanofi.com/en/our-science/our-pipeline\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Rare Diseases \u0026 Blood Disorders R\u0026D - Sanofi\",\"description\":\"Back in 1991, we delivered the first successful enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder (LSD). Thereafter, treatments forÂ ...Missing:  achievements | Show results with:achievements\",\"url\":\"https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases-research-development\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Pipeline\",\"description\":\"For an overview of the current Sanofi Rare Diseases Pipeline, view our full list of investigational agents Click here.Missing:  Genzyme | Show results with:Genzyme\u003c|separator|\u003e\",\"url\":\"https://www.rarediseases.sanofimedical.com/Pipeline\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Genzyme veteran, biotech pioneer on the 'orphan drug revolution'\",\"description\":\"Dec 15, 2022 Â· Genzyme was the first company to develop the orphan-drug business model. And that business model, of course, the prices had to be sustainable.\",\"url\":\"https://www.bizjournals.com/boston/news/2022/12/15/boston-area-biotech-pioneer-on-the-orphan-drug-re.html\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"The path less costly | Nature Biotechnology\",\"description\":\"Oct 13, 2010 Â· In 1991, the company obtained approval for Ceredase (alglucerase injection), an enzyme replacement therapy for lysosomal storage disease (LSD)Â ...\",\"url\":\"https://www.nature.com/articles/nbt1010-1018\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Biotechnology-based Orphan Drugs - Achievements and challenges\",\"description\":\"Oct 2, 2003 Â· In the 1980s, when Genzyme first began developing CeredaseÂ® as a treatment for Gaucher disease, the number of patients in need of treatmentÂ ...\",\"url\":\"https://www.ddw-online.com/biotechnology-based-orphan-drugs-achievements-and-challenges-1584-200310/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Alglucerase injection (CeredaseÂ®) â€“ Gaucher disease\",\"description\":\"Dec 3, 2024 Â· The recombinant product CerezymeÂ®, was approved by the FDA in 1994, and shown to be as effective for the treatment of Type 1 Gaucher disease asÂ ...\",\"url\":\"https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/alglucerase-injection-ceredaser-gaucher-disease\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Genzyme: Engineering the Market for Orphan Drugs - Case\",\"description\":\"Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies.\",\"url\":\"https://www.hbs.edu/faculty/Pages/item.aspx?num=28922\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and ...\",\"description\":\"Jul 28, 2011 Â· Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms. Positive impact from Genzyme on business EPS(1).Missing:  jobs | Show results with:jobs\",\"url\":\"https://www.prnewswire.com/news-releases/sanofi-sales-growth-of-69-thanks-to-genzyme-acquisition-and-performance-of-growth-platforms-126311908.html\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Clinical Studies | CerezymeÂ® (imiglucerase)\",\"description\":\"The study found that long-term treatment with Cerezyme reduced organ, blood, and bone problems in patients with Gaucher disease type 1.\",\"url\":\"https://www.cerezyme.com/considering-cerezyme/clinical-studies\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Enzyme Replacement Therapies: Better Lives Versus the Bottom Line\",\"description\":\"Enzyme replacement therapies promise improvement or even a second chance at life for patients with ultra-rare diseases.Missing:  achievements | Show results with:achievements\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3564370/\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Enzyme replacement therapy: improving outcomes in rare disease\",\"description\":\"Sep 12, 2024 Â· The company's enzyme replacement therapy Xenpozyme (olipudase alfa) has promise for the rare genetic disease acid sphingomyelinase deficiency (ASMD).\",\"url\":\"https://www.europeanpharmaceuticalreview.com/article/233622/enzyme-replacement-therapy-improving-outcomes-in-rare-disease/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Genzyme to buy Novazyme - MarketWatch\",\"description\":\"Aug 7, 2001 Â· CAMBRIDGE, Mass. (CBS.MW) -- Genzyme said Tuesday it will buy Novazyme Pharmaceuticals for up to $225 million in an all-stock deal aimed atÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.marketwatch.com/story/genzyme-to-buy-novazyme-for-up-to-225-million\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"FTC Closes its Investigation of Genzyme Corporation's 2001 ...\",\"description\":\"Jan 13, 2004 Â· The Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme).\u003c|separator|\u003e\",\"url\":\"https://www.ftc.gov/news-events/news/press-releases/2004/01/ftc-closes-its-investigation-genzyme-corporations-2001-acquisition-novazyme-pharmaceuticals-inc\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Genzyme and Isis Announce Strategic Alliance Including Exclusive ...\",\"description\":\"Jan 7, 2008 Â· Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisenseÂ ...\",\"url\":\"https://ir.ionis.com/news-releases/news-release-details/genzyme-and-isis-announce-strategic-alliance-including-exclusive\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"\",\"description\":\"\",\"url\":\"https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-and-genzyme-announce-restructuring\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Genzyme Detects Virus Contamination of Bioreactor, Halts Production\",\"description\":\"Jun 17, 2009 Â· Genzyme Corporation has halted production at its manufacturing plant in Allston Landing, MA, because it has detected a virus that impairs cell growth.\",\"url\":\"https://www.biopharminternational.com/view/genzyme-detects-virus-contamination-bioreactor-halts-production\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Genzyme Drug Shortage Leaves Users Feeling Betrayed\",\"description\":\"Apr 15, 2010 Â· Production problems with two drugs for rare inherited diseases have left patients in pain and may have led to one death.Missing:  impact 2009-2011\",\"url\":\"https://www.nytimes.com/2010/04/16/business/16genzyme.html\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"[PDF] Genzyme Corporation, Allston, MA, FDA Form 483 11/13/2009\",\"description\":\"Nov 13, 2009 Â· The fill equipment has been in place and in use since 1994 and used for filling of drug products including, Myozyme, Fabrazyme,. Cerezyme, andÂ ...\",\"url\":\"https://www.fda.gov/about-fda/genzyme-corporation-allston-ma-fda-form-483-11132009\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Sanofi's Genzyme Sees Limited Cerezyme Supplies Through January\",\"description\":\"Sep 15, 2011 Â· A 2009 virus contamination at Genzyme's manufacturing plant in Allston, Massachusetts, led to shortages of Cerezyme and Fabrazyme ... productionÂ ...\",\"url\":\"https://www.bloomberg.com/news/articles/2011-09-15/sanofi-s-genzyme-sees-limited-cerezyme-supplies-through-january\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Genzyme Corp. to Pay $22.28 Million to Resolve False Claims ...\",\"description\":\"Dec 20, 2013 Â· Genzyme Corp. has agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state healthÂ ...Missing:  marketing off- label\",\"url\":\"https://www.justice.gov/archives/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Whistleblower lawsuit costs Genzyme $22M - MassDevice\",\"description\":\"Jan 3, 2014 Â· The company told reporters that it has taken measures to cooperate with federal investigations and to put a stop to all off-label marketing,Â ...Missing:  practices promotion\u003c|separator|\u003e\",\"url\":\"https://www.massdevice.com/whistleblower-lawsuit-costs-genzyme-22m/\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Genzyme Corporation to Pay $32.5 Million to Resolve Criminal ...\",\"description\":\"Sep 3, 2015 Â· Genzyme Corporation to Pay $32.5 Million to Resolve Criminal Liability Relating to Seprafilm. Thursday, September 3, 2015. For Immediate Release.\",\"url\":\"https://www.justice.gov/archives/opa/pr/genzyme-corporation-pay-325-million-resolve-criminal-liability-relating-seprafilm\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"[PDF] v. DEFERRED PROSECUTION AGREEMENT -1 - - Gibson Dunn\",\"description\":\"Aug 31, 2015 Â· Although Genzyme prohibited \\\"off-label promotion,\\\" Genzyme permitted its sales representatives to discuss slurry with physicians with certainÂ ...\",\"url\":\"https://www.gibsondunn.com/wp-content/uploads/documents/publications/Genzyme-DPA-and-Attachments.pdf\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"State of New Jersey\",\"description\":\"Mar 12, 2014 Â· As part of the overall Genzyme settlement, New Jersey will receive $102,000 in restitution and other recoveries. ####.Missing:  Synvisc | Show results with:Synvisc\",\"url\":\"https://nj.gov/oag/newsreleases14/pr20140312a.html\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Sanofi's Genzyme pays $32.59 million in criminal Seprafilm case\",\"description\":\"Sep 3, 2015 Â· In December 2013, Genzyme reached a $22.28 million civil agreement to resolve claims related to Seprafilm under the federal False Claims Act.\",\"url\":\"https://ca.finance.yahoo.com/news/sanofis-genzyme-pays-32-59-million-criminal-seprafilm-000515813--finance.html\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"[PDF] ATTACHMENT B - Department of Justice\",\"description\":\"Sep 3, 2015 Â· Based on the conduct of some Genzyme employees before the acquisition, Genzyme agreed to enter into civiil and criminal settlements with the.\",\"url\":\"https://www.justice.gov/d9/press-releases/attachments/2015/09/03/genzyme_dpa_attachment_b.pdf\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Genzyme to Pay $32.5M for False Marketing of Seprafilm\",\"description\":\"Sep 4, 2015 Â· Genzyme Corp. agreed in a deferred prosecution agreement filed Sept. 3 to pay $32.6 million to settle a U.S. criminal probe into theÂ ...Missing:  Synvisc | Show results with:Synvisc\",\"url\":\"https://news.bloomberglaw.com/white-collar-and-criminal-law/genzyme-to-pay-325m-for-false-marketing-of-seprafilm\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Appeals court revives litigation centered on Sanofi's Fabrazyme\",\"description\":\"Feb 20, 2024 Â· In 2011, Genzyme â€œworsenedâ€ the U.S. shortage by diverting some supply to Europe, plaintiffs have argued. Fabrazyme supply recovered in 2012,Â ...\",\"url\":\"https://www.fiercepharma.com/pharma/fabrazyme-litigation-back-play-sanofi-and-its-genzyme-appeals-court-overturns-dismissal-2020\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"[PDF] Genzyme-Fourth-Amended-Complaint.pdf - STAT News\",\"description\":\"The above email shows that at the time Genzyme decided to supply patients with a 0.3 mg/kg doses of FabrazymeÂ®, Genzyme knew that shortages in FabrazymeÂ® supplyÂ ...\",\"url\":\"https://www.statnews.com/wp-content/uploads/2024/02/Genzyme-Fourth-Amended-Complaint.pdf\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Fabry Patients Sue Genyzme for Damages Caused By Fabrazyme ...\",\"description\":\"Mar 10, 2011 Â· Genzyme currently rations patient access to 50% of the FDA approved dosage and does not approve new patients for Fabrazyme treatment.Missing:  disputes | Show results with:disputes\",\"url\":\"https://patentdocs.org/2011/03/10/fabry-patients-sue-genyzme-for-damages-caused-by-fabrazyme-rationing/\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"To march in or not to march in - Nature\",\"description\":\"Europe, in contrast, continues to receive full doses of Fabrazyme sufficient to treat up to 400 people (Mol. Genet. Metab. 102, 99â€“102,. 2011). Genzyme, for itsÂ ...Missing:  disputes | Show results with:disputes\",\"url\":\"https://www.nature.com/articles/nm.2440.pdf\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Hochendoner v. Genzyme Corp., No. 15-1446 (1st Cir. 2016)\",\"description\":\"Despite setbacks in reestablishing production levels, in 2011 Genzyme diverted some Fabrazyme to the European market, allegedly because of competition GenzymeÂ ...\",\"url\":\"https://law.justia.com/cases/federal/appellate-courts/ca1/15-1446/15-1446-2016-05-23.html\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Cutting Dosage of Costly Drug Spurs a Debate - The New York Times\",\"description\":\"Mar 16, 2008 Â· In the case of Genzyme's Cerezyme, higher doses are not harmful. It is only a question of how much of the drug is needed, given the cost. SomeÂ ...\",\"url\":\"https://www.nytimes.com/2008/03/16/business/16gaucher.html\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Review of the safety and efficacy of imiglucerase treatment of ... - NIH\",\"description\":\"The dosage controversy has never been adequately resolved., The first and possibly overriding concern was the cost, but beyond this was the question ofÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2747339/\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Impact of Imiglucerase Supply Shortage on Clinical and Laboratory ...\",\"description\":\"The aim of this retrospective analysis is to describe the effects of the imiglucerase shortage in adults with N-GD3 to increase the knowledge of therapy effectsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4289531/\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"[PDF] Questions and answers on the shortages of Cerezyme and Fabrazyme\",\"description\":\"Jun 25, 2009 Â· While the shortages are ongoing, they may be treated at the same frequency. (every two weeks) but with a reduced dose. â€¢ Patients who have anyÂ ...Missing:  controversy | Show results with:controversy\",\"url\":\"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-shortages-cerezyme-and-fabrazyme_en.pdf\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Search Orphan Drug Designations and Approvals - FDA\",\"description\":\"Marketing approved: ; Fabrazyme Â· 03/11/2021 Â· treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease Â· 03/11/2028.\",\"url\":\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=15286\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"[PDF] 761161Orig1s000 - accessdata.fda.gov\",\"description\":\"May 8, 2023 Â· The Division has required all newly approved ERTs to have a Boxed Warning (BW) for hypersensitivity reactions including anaphylaxisÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"[PDF] GENZYME CORPORATION. - GovInfo\",\"description\":\"Mar 30, 2012 Â· Wyzga told investors that. Cerezyme and Fabrazyme had contributed to top-line growth due to increases in patient accruals, and Termeer toldÂ ...\",\"url\":\"https://www.govinfo.gov/content/pkg/USCOURTS-mad-1_09-cv-11299/pdf/USCOURTS-mad-1_09-cv-11299-0.pdf\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Genzyme Successfully Meets First Milestones of FDA Consent Decree\",\"description\":\"Nov 24, 2010 Â· Genzyme Successfully Meets First Milestones of FDA Consent Decree ... 2009 revenues of $4.5 billion. In 2010, Genzyme was named to theÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://www.fiercebiotech.com/biotech/genzyme-successfully-meets-first-milestones-of-fda-consent-decree\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"FDA Approves Genzyme Corporation's Myozyme(R) For All Patients ...\",\"description\":\"Apr 28, 2006 Â· FDA Approves Genzyme Corporation's Myozyme(R) For All Patients With Pompe Disease; Drug To Carry Warning. CAMBRIDGE, Mass., April 28 /Â ...\u003c|separator|\u003e\",\"url\":\"https://www.biospace.com/fda-approves-genzyme-corporation-s-myozyme-r-for-all-patients-with-pompe-disease-drug-to-carry-warning\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Genzyme Announces European Approval of Framingham ...\",\"description\":\"Jan 18, 2012 Â· \\\"This approval by the EMA represents an important milestone in our manufacturing recovery and path toward unconstrained supply for all patients,Â ...Missing:  interactions | Show results with:interactions\",\"url\":\"https://www.fiercepharma.com/pharma/genzyme-announces-european-approval-of-framingham-manufacturing-plant\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Genzyme: The Price of Success | PharmExec\",\"description\":\"In 2005, LSDs brought in $1.3 billion, or 48 percent of Genzyme's total revenues. Cerezyme accounted for most of that, pulling in $932 million. Fabrazyme jumpedÂ ...\",\"url\":\"https://www.pharmexec.com/view/genzyme-price-success\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"High prices make once-neglected 'orphan' drugs a booming business\",\"description\":\"Aug 4, 2016 Â· Henri Termeer, then the chief executive of the Massachusetts biotechnology company Genzyme, appeared before Congress to argue against the cap,Â ...\",\"url\":\"https://www.washingtonpost.com/business/economy/high-prices-make-once-neglected-orphan-drugs-a-booming-business/2016/08/04/539d0968-1e10-11e6-9c81-4be1c14fb8c8_story.html\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"NIH faces marching orders on orphan drug shortage | Nature Medicine\",\"description\":\"May 5, 2011 Â· NIH faces marching orders on orphan drug shortage. Elie Dolgin. Nature Medicine volume 17, page 522 (2011)Cite this article.\",\"url\":\"https://www.nature.com/articles/nm0511-522b\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Orphan Drug Act: Fostering Innovation or Abuse?\",\"description\":\"Dec 12, 2017 Â· A special report exploring the high price of orphan drugs and found that pharmaceutical companies are potentially abusing the orphan drug incentives created byÂ ...Missing:  property | Show results with:property\",\"url\":\"https://sourceonhealthcare.org/orphan-drug-act-fostering-innovation-or-abuse/\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"[PDF] 1016/1/1/03 Genzyme Limited - Judgment [2005] CAT 32\",\"description\":\"Mar 11, 2004 Â· ... Genzyme's arguments in relation to orphan drugs. We note that the rights accorded to orphan drugs under Article. 8(1) of Regulation 141/2000Â ...\",\"url\":\"https://www.catribunal.org.uk/sites/cat/files/Jdg1016Genzy110304.pdf\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Genzyme Corporation Launches Initiative To Assist The ... - BioSpace\",\"description\":\"Apr 11, 2006 Â· Genzyme has begun one of its first projects in partnership with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit drugÂ ...\",\"url\":\"https://www.biospace.com/genzyme-corporation-launches-initiative-to-assist-the-development-of-treatments-for-neglected-diseases\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Orphans in the Market: The History of Orphan Drug Policy\",\"description\":\"Nov 27, 2017 Â· The Machinery of Orphan Drugs. The 1983 Orphan Drug Act retained the provisions for seven-year exclusive marketing rights and tax creditsÂ ...Missing:  intellectual property\",\"url\":\"https://academic.oup.com/shm/article/32/3/609/4663001\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"Sanofi-Aventis Completes Acquisition of Genzyme Corporation\",\"description\":\"Apr 8, 2011 Â· Genzyme will become an important new platform in sanofi-aventis' sustainable growth strategy and expand the company's presence in biotechnology.\",\"url\":\"https://www.prnewswire.com/news-releases/sanofi-aventis-completes-acquisition-of-genzyme-corporation-119496769.html\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Sanofi moves deeper into Genzyme operations - Fierce Pharma\",\"description\":\"Jun 15, 2011 Â· And now, Sanofi has announced an R\u0026D structure that will coordinate Sanofi and Genzyme programs through an umbrella unit called the SanofiÂ ...\",\"url\":\"https://www.fiercepharma.com/pharma/sanofi-moves-deeper-into-genzyme-operations\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Sanofi putting its stamp on Genzyme - Boston.com\",\"description\":\"Jun 14, 2011 Â· ... Sanofi rolled out a new reporting structure for Genzyme's marketing and sales business units. In an employee bulletin, Sanofi said GenzymeÂ ...\",\"url\":\"https://www.boston.com/uncategorized/noprimarytagmatch/2011/06/14/sanofi-putting-its-stamp-on-genzyme/\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Sanofi: 2011 Results Benefit from Genzyme Acquisition - Feb 8, 2012\",\"description\":\"Feb 8, 2012 Â· In 2011, the growth platforms and Genzyme comprised 65.0% of total consolidated sales compared with 56.9% in 2010. Full year 2011 sales ofÂ ...Missing:  details | Show results with:details\",\"url\":\"https://www.news.sanofi.us/press-releases?item=121274\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"Sanofi announces new Global Business Unit structure\",\"description\":\"Jul 15, 2015 Â· The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of Sanofi's medicines in RareÂ ...\",\"url\":\"https://www.europeanpharmaceuticalreview.com/news/33346/sanofi-announces-new-global-business-unit-structure/\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"SANOFI ANNOUNCES NEW, GLOBAL BUSINESS UNIT ...\",\"description\":\"Nov 6, 2015 Â· The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of Sanofi's medicines in RareÂ ...\",\"url\":\"https://www.fiercepharma.com/pharma/sanofi-announces-new-global-business-unit-structure-to-drive-future-growth\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Sanofi-Genzyme: Still successful 5 years after the acquisition\",\"description\":\"Feb 23, 2023 Â· Genzyme was acquired by Sanofi for $20Bn back in 2011, which is one of the biggest Biotech deals in history. For many people, Genzyme'sÂ ...Missing:  founding achievements\",\"url\":\"https://www.labiotech.eu/trends-news/sanofi-genzyme-acquisition/\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Post-merger Genzyme opens up the throttle on R\u0026D plans\",\"description\":\"Apr 27, 2011 Â· Genzyme, meanwhile, plans to position Campath with a biomarker program expected to flag patients who can be safely treated with the drug.Missing:  acquisition | Show results with:acquisition\",\"url\":\"https://www.fiercebiotech.com/biotech/post-merger-genzyme-opens-up-throttle-on-r-d-plans\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"Rare Blood Disorders - Sanofi\",\"description\":\"Hemophilia, a rare genetic blood disorder that impairs the ability of blood to clot, is the cornerstone of the Rare Blood Disorders franchise.\",\"url\":\"https://www.sanofi.com/en/our-science/therapeutic-areas/rare-blood-disorders\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"[PDF] strong Q1 performance and 2025 guidance confirmed - Sanofi\",\"description\":\"Apr 24, 2025 Â· Sanofi has 86 projects in a pipeline across four main disease areas (Immunology, Rare diseases, Neurology, and Oncology) and. Vaccines,Â ...\u003c|separator|\u003e\",\"url\":\"https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-04-24-05-30-00-3067075-en.pdf\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Sanofi 2025: From the incurable to the manageable - PharmaLive\",\"description\":\"Oct 7, 2025 Â· ... new medicines such as rilzabrutinib in rare diseases and tolebrutinib in multiple sclerosis. We are also confident in the mid-to-long-termÂ ...\",\"url\":\"https://www.pharmalive.com/sanofi-2025-from-the-incurable-to-the-manageable/\",\"favicon\":\"\"}],\"images\":[{\"id\":\"657bd2fed01b\",\"caption\":\"Genzyme headquarters\",\"url\":\"./_assets_/Genzyme_building.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"28061d95a3e3\",\"caption\":\"Genzyme plant in Allston, Massachusetts\",\"url\":\"./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"28061d95a3e3\",\"caption\":\"Genzyme Allston plant\",\"url\":\"./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"28061d95a3e3\",\"caption\":\"Genzyme plant, Allston, Massachusetts\",\"url\":\"./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"28061d95a3e3\",\"caption\":\"Genzyme plant, Allston, Massachusetts\",\"url\":\"./_assets_/Genzyme_plant%252C_Allston%252C_Massachusetts.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Genzyme\",\"title\":\"Genzyme\",\"content\":\"$1f\",\"description\":\"Genzyme\\n\\nGenzyme headquarters \\nGenzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based...\",\"metadata\":{\"categories\":[\"Genzyme Corporation\",\"Sanofi Genzyme\",\"Genzyme Corp\"],\"lastModified\":\"1761583101\",\"contentLength\":\"75062\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"30862\",\"recentViews\":\"30862\",\"dailyAvgViews\":1028.7332763671875,\"qualityScore\":1,\"lastViewed\":\"1761885660\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761885660384,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Genzyme\"],\"queryHash\":\"[\\\"page\\\",\\\"Genzyme\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Genzyme\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Genzyme Corporation, Sanofi Genzyme, Genzyme Corp\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Genzyme\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Genzyme\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Genzyme\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Genzyme\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:43.101Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Genzyme\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Genzyme Corporation was an American biotechnology company founded in 1981 by enzymologist Henry Blair in Cambridge, Massachusetts, initially to develop enzyme-based products in collaboration with the National Institutes of Health. The firm specialized in therapies for rare genetic disorders, particularly lysosomal storage diseases, pioneering recombinant enzyme replacement treatments that addressed previously unmet needs in small patient populations. Under the leadership of subsequent...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="M2Y1MDRiYTctODM3Ny00Yzg5LTg0YzEtNWRmM2ExMzYwNDFk">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Genzyme\"}]}]\n"])</script></body></html>